Center for Vaccine Ethics & Policy (CVEP)

Vaccines and Global Health: The Week in Review

14 November 2026 :: Issue 868

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. Th e PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director, Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: Milestones, Perspectives
:: WHO
:: U.S. Immunization and Public Health Governance/Policy/Funding
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
:: Think Tanks
:: Public Consultations/Call for Inputs/Call for Papers

Milestones, Perspectives

::::::::
::::::::

PABS Annex

Member States reiterate commitment to finalize Pandemic Agreement PABS Annex by May 2027

WHO News release, Geneva 13 November 2026
[Editor's text bolding]
Member States advanced negotiations on the Pathogen Access and Benefit-Sharing (PABS) Annex to the WHO Pandemic Agreement, **reaffirming their commitment to finalizing the Annex for its consideration by the World Health Assembly in May 2027…**

The two-weeks long negotiations of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement reflected a strong determination among Member States to fulfill the mandate they set for themselves when adopting the Pandemic Agreement.

"During the past two weeks, government negotiators have worked tirelessly and constructively to move the Pathogen Access and Benefit Sharing annex and agenda forward," said Ambassador Tovar da Silva Nunes of Brazil, co-chair of the IGWG Bureau guiding the negotiations. **"We have made important progress on both benefit-sharing and access provisions, while maintaining a shared focus on building a system that is practical, equitable and capable of delivering public health benefits when they are needed most."**

Member states made progress on how to share benefits within a legally binding framework. Their discussions further clarified the roles of participating partners and explored how the PABS system can support more equitable access to pandemic-related health products when future threats emerge.

Member States also advanced discussions on access to pathogens with pandemic potential, including the sharing of biological materials and sequence information, **while undertaking detailed consideration of the role of laboratories and other technical partners in supporting the system.**

IGWG Bureau co-chair, Ambassador Anne-Claire Amprou of France, said: "The spirit of these discussions has been remarkably constructive. **Through both formal and informal negotiations, Member States have demonstrated a strong commitment to finding common ground and refining the Annex so that we can meet the mandate entrusted to us and conclude our work by the next World Health Assembly in May 2027."**

Throughout the negotiations, WHO experts continued to support Member States with scientific, legal and operational expertise that informed discussions and pushed for progress across complex issues.

At the meeting's closing, WHO Director-General Dr Tedros Adhanom Ghrebreyesus, recognized the progress of Member States in taking the PABS Annex negotiations forward, and reminded them of the importance of their work to help make the world safer from future pandemic threats.

"I am reassured to hear the full commitment of delegations to conclude the negotiations in time for the World Health Assembly next year," said Dr Tedros. "What we need now is to translate that

commitment into reality in the room, and to move decisively towards concluding the text. I have seen signs of that during IGWG9, and I hope you will carry that momentum forward."

Member States agreed to keep momentum in the coming months, including working to bring positions closer together through informal sessions. IGWG9 will resume formal negotiations during 11-15 January 2027. Additional rounds of formal negotiations are scheduled for 15-19 February 2027 and 15-25 March 2027…

::::::::

A/IGWG/9 - Intergovernmental Working Group [IGWG] on the WHO Pandemic Agreement – 02-13 November 2026
The IGWG serves as a platform for countries to collaboratively shape the operational details of the WHO Pandemic Agreement. The Group's work includes the development of an annex on Pathogen Access and Benefit Sharing (PABS) – a system designed to ensure transparent and equitable sharing of pathogen samples and genetic sequence data.
:: A/IGWG/9/1 - Provisional agenda
:: A/IGWG/9/2 - Draft programme of work

GWG9 - Session 1
Item 1 - Opening of the session and adoption of the agenda and programme of work
02/11/2026 – Video: 09:15-10:45

IGWG9 - Session 2
Item 1 (continued) - Election of the IGWG Officer
03/11/2026 - 09:20-09:30

IGWG9 - Session 3
Item 5 & 6 - Report of the meeting and Closure of the session
03/11/2026 - 17:15-17:55

Written statements by Relevant Stakeholders – IGWG /9{ 2-13 November 2026
:: AHF Brasil and Third World Network (TWN)
:: DSMZ
:: IUHPE
:: KEI
:: PREZODE

::::::::

Editor's Note
We encountered the Call for Inputs on the PABS Annex [below] from the UN Special Rapporteur on the Right to Health just as we were listening to the closing session of the IGWG/9 and had just read the WHO news release reporting on the sessions [above]. We immediately noted the juxtaposition in time between:
:: the long-established goal of the IGWG PABS negotiations to produce a solution able to be considered and presumably adopted at the next World Health Assembly [Sunday, 23 May 2027 - Sunday, 30 May 2027] and,
:: the stated outcome of the call for input to support a thematic report to be delivered at the 65th session of Human Rights Council [June 2027].

We have reached out to the Special Rapporteur on the Right to Health to request clarification on this timing and the practical impact [positive/negative; intended/unintended] that such a report might make.

Call for Inputs – Pathogen Access and Benefit-Sharing (PABS) System, equitable access and the right to health in pandemic prevention, preparedness and response [HRC65 Report (Special Rapporteur on Right to Health)]

OHCHR - Special Procedures

Issued by Special Rapporteur on the right to health **Deadline: 14 December 2026**

Purpose

To inform the Special Rapporteur on Right to Health's thematic report to the HRC 65th session on the Pathogen Access and Benefit-Sharing (PABS) System, equitable access and the right to health in pandemic prevention, preparedness and response.

Background

The Special Rapporteur will present a thematic report to the 65th session of Human Rights Council (June 2027) on the Pathogen Access and Benefit-Sharing (PABS) System established under article 12 of the World Health Organization (WHO) Pandemic Agreement, including the PABS Annex, which remains under negotiation, and questions of implementation. The report asks whether, and how, this system can help ensure that when the next pandemic comes, vaccines, treatments and tests reach the people who need them, when they need them and wherever they live.

The Special Rapporteur would like to hear from everyone who will shape, use or depend on the PABS System: Member States, international organizations, researchers, manufacturers, national human rights institutions and civil society, and in particular people and communities who lived through unequal access during COVID-19 and other public health emergencies. You do not need to be an expert in pathogen sharing to respond. Accounts of what happened in your country or community are as valuable as legal or technical analysis.

Objectives

The report will examine how the design and implementation of the PABS System can contribute to the realization of the right of everyone to the highest attainable standard of physical and mental health and related human rights. It will focus in particular on equity and non-discrimination; the availability, accessibility, acceptability and quality of pandemic-related health products; the right to enjoy the benefits of scientific progress; participation and access to information; transparency, monitoring and accountability; international assistance and cooperation; and the protection of persons in vulnerable situations. **It will also examine how human rights standards can inform research and innovation governance from the outset, including benefit-sharing, technology transfer, licensing and production, and how national and regional ABS measures can support, rather than duplicate or undermine, the PABS System**. It will seek to bridge the technical language of access and benefit-sharing and the language of human rights, so that negotiators, health authorities, human rights bodies and affected communities can work from a shared understanding.

Key questions and types of input/comments sought

The questionnaire can be downloaded below in English (original language), French and Spanish (unofficial translations). You may answer all or only some of the questions, according to your experience.

Respondents are encouraged to provide concrete examples, disaggregated data, research, legal analysis and lessons learned from previous health emergencies and existing access and benefit-sharing mechanisms. Submissions may also identify good

practices and protection gaps, and propose specific measures that States, WHO, other international organizations, business enterprises and other non-State actors could take, consistent with their respective obligations, mandates and responsibilities, to ensure that the PABS System contributes effectively to equitable access and the realization of the right to health.

1. **Lessons from COVID-19**. What did you see or experience of unequal access to vaccines, therapeutics, diagnostics and other essential health services during COVID-19 or other health emergencies? What caused or worsened these inequalities, and what should be visibly different in the next pandemic for the PABS System to be considered a success? You may wish to consider health-system capacity, financing, workforce shortages, supply chains, intellectual property and licensing, digital or administrative barriers, discrimination and social determinants of health.
2. **PABS and the right to health.** How can the PABS System help ensure that pandemic-related health products are available, physically and economically accessible without discrimination, acceptable and of good quality? How should human rights inform research and innovation from the outset, and how should the System give practical effect to the relationship between the right to health and the right to enjoy the benefits of scientific progress? You may wish to consider research financing, data and sequence information, intellectual property, licensing, technology transfer, manufacturing and procurement.
3. **Equality, equity and people left behind.** Which countries, populations and communities faced the greatest barriers to vaccines, therapeutics, diagnostics and essential health services during COVID-19 and other health emergencies, and why? How should the PABS System and national allocation and distribution arrangements address inequalities linked to poverty, gender, age, disability, race, ethnicity, migration status, place of residence and other intersecting factors? What measures are needed to ensure that international allocation according to public health risk and need translates into equitable access within countries?
4. **Participation, information and transparency.** How can States, particularly developing countries, and affected communities, civil society, health workers, researchers and scientists participate meaningfully in the governance, monitoring and review of the PABS System? What information should be publicly available, subject to legitimate confidentiality and data-protection safeguards, and what would make decision-making understandable and open to public scrutiny? You may wish to consider information on users, contracts, benefit-sharing commitments, allocation criteria, implementation, traceability and access to PABS data.
5. **Private actors.** What should pharmaceutical and biotechnology companies and sequence database operators do to meet their responsibility to respect human rights under the UN Guiding Principles on Business and Human Rights? What measures should States take, consistent with their duty to protect against business-related human rights abuse, and how can WHO use its contractual, convening and administrative functions within the PABS System to promote compliance and equitable access?
6. **Monitoring and accountability.** How will we know whether the PABS System is producing equitable, rights-consistent outcomes? Which indicators should be monitored and, where relevant, disaggregated; what information should be published, including on users, contracts, monetary and non-monetary benefits, allocation and delivery; and what independent monitoring, accountability and remedy mechanisms should apply when commitments are not met or inequitable outcomes persist?
7. **Cooperation and solidarity.** How should States' obligations of international assistance and cooperation inform the design and implementation of the PABS System? How can pathogen access and benefit-sharing operate on an equal footing, including through predictable financing, research cooperation, technology transfer, non-exclusive licensing, geographically diversified production and timely allocation based on public health risk and need? What safeguards are needed so that these commitments are in place before a crisis,

rather than depending on goodwill once it starts, and how far would inequitable benefit-sharing undermine the effectiveness of the Pandemic Agreement as a whole?

8. **Access and benefit-sharing instruments**. What elements should the PABS Annex and relevant national or regional ABS laws and policies contain to give effect to the Pandemic Agreement while ensuring consistency, legal certainty and human rights protection? How should national and regional measures be aligned with the PABS System so that they support rapid pathogen sharing and equitable benefit-sharing without creating inconsistent or duplicative requirements within its scope? Beyond the scope of the PABS System, how could national frameworks build lasting, rights-based benefit-sharing mechanisms for public health? Please share examples of existing frameworks and what they have achieved, including evidence of their human rights impacts or outcomes.

Next Steps

Input/comments may be sent by email. They must be received by 14 December 2026 .

We kindly request that submissions be concise and limited to a maximum of five pages (or 2,500 words). Respondents may address all or only some of the questions above, depending on their areas of expertise and experience. Supporting documents may be attached. We sincerely appreciate your valuable contributions to this report and your continued cooperation with the mandate. Where relevant information has already been submitted to other special procedures or human rights mechanisms, respondents are encouraged to refer to those submissions to avoid duplication and facilitate coordination.

For any questions or further information, please contact the mandate of the Special Rapporteur at hrc-sr-health@un.org.

Email address: hrc-sr-health@un.org Email subject line: Submission for HRC65 Report
Word/Page limit: 2500 words / 5 pages Accepted file formats: Word
Accepted Languages: English, French, Spanish
Documentation: Download the CFI in PDF: English | Français | Español

::::::::
::::::::

Trust in Science

WHO launches "Together for Science and Health" movement to strengthen trust worldwide

10 November 2026 *News release* Geneva/Paris/Brazzaville/New Delhi

The World Health Organization (WHO) today launched Together for Science and Health, **a new global movement uniting more than 240 organizations behind a shared commitment to strengthen trust in science and harness its power to improve health and development.**

With an official launch on World Science Day for Peace and Development, **the movement rallies scientists, leaders, policy-makers and institutions across sectors, with 12 events taking place across countries and regions to mark the occasion…**

WHO Director-General, Dr Tedros Adhanom Ghebreyesus, and French President Emmanuel Macron are leading the launch. **"Science is one of humanity's most powerful tools, and has always been the engine of better health," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Science has enabled people to live longer, healthier lives through vaccines, medicines, disease prevention and outbreak response.** Through the Together for Science and Health Movement, WHO and partners are working together to champion evidence, trust and innovation as the foundations of healthier societies."…

Declaration of Commitment:

DECLARATION OF COMMITMENT

Together for SCIENCE & HEALTH

Collective action to advance health for all

By endorsing Together for Science and Health, we affirm our commitment to advancing science as a global public good that serves health, equity, and societal wellbeing. We engage in this movement to promote scientific integrity, ethical responsibility, and social inclusion, and to strengthen the connection between science, policy, and society.

We commit to supporting evidence informed decision making, fostering transparent and trustworthy scientific processes, and participating in inclusive dialogue that values diverse knowledge systems and lived experience. Through collective action, collaboration, and responsible use of innovation, we seek to ensure that scientific progress translates into tangible and equitable health benefits for all, now and for future generations.

We commit to the following core principles:

R **Respect**
Recognition and integration of diverse sources of knowledge, lived experience, cultural perspectives and community expertise are critical to advancing science

I **Integrity**
Honesty, transparency and accountability are essential to the trustworthy development and application of science, particularly in emerging technologies

S **Scientific rigor**
Robust methods, critical inquiry, peer review and continuous learning underpin the generation, dissemination and application of scientific knowledge

E **Ethical responsibility**
Strong ethical standards ensure that scientific progress advances the public good while respecting dignity, promoting equity and upholding human rights

S **Social inclusion**
Social participation and the active listening of diverse voices, particularly those of people and communities most affected, ensure that science responds to societal needs and benefits all

We commit to and agree to champion the shared **RISES** values of Together for Science and Health that ensure science remains credible, ethical and socially relevant in today's world.

Affiliation partner signature

Date

::::::::
::::::::

TB

Amid challenges, countries increase domestic investment to protect progress against tuberculosis
12 November 2026 *WHO News release*

Global tuberculosis report 2026
12 November 2026 | *Global report*
PDF: https://iris.who.int/server/api/core/bitstreams/726b4727-ac22-432d-96e7-563210b8fb32/content
Overview
The WHO Global tuberculosis report 2026 provides a comprehensive assessment of the tuberculosis (TB) epidemic and progress in prevention, diagnosis and treatment at global, regional and country levels, in the context of international commitments and targets. Based primarily on data reported to WHO by 187 countries and areas representing more than 99% of the world's population and TB cases, the report presents updated estimates of disease burden and trends in the global TB response.

In 2025, an estimated 10.6 million people developed TB and 1.13 million died from the disease. Although TB incidence and mortality declined, progress remained substantially below the milestones of the WHO End TB Strategy.

The report highlights persistent gaps in diagnosis, treatment, prevention and financing, emphasizing the need for sustained investment and strengthened health services. Estimates of TB disease burden should be interpreted using the latest published time series, as direct comparisons with estimates from previous editions are not appropriate.
Global TB reports from previous years can be found here.

[Excerpt]
4. Conclusions
All WHO and UN Member States have committed to ending the global TB epidemic, through their adoption of the End TB Strategy and SDGs. The 2030 targets of the End TB Strategy are a 90% reduction in the number of deaths caused by TB and an 80% reduction in the TB incidence rate, compared with levels in 2015.

These commitments were reaffirmed at two UN high-level meetings on TB, held in 2018 and 2023, and reinforced with additional targets related to funding, the provision of treatment to people with TB disease or TB infection, and the availability of new TB vaccines.

TB remains a major global public health problem, and progress in reducing the burden of disease falls far short of 2030 targets in most parts of the world. Nonetheless, important global progress has been made, especially in reducing the number of people dying from TB each year.

In 2025, a significant global milestone was reached: a 35% reduction in the global number of deaths caused by TB compared with 2015, albeit 5 years behind the original schedule set out in the End TB Strategy. The number of people dying from TB each year has been halved in two WHO regions: the African Region and the European Region. A total of 99 countries have reduced the TB incidence rate by 20% or more since 2015, and 89 countries have reduced the number of people dying from TB by at least 35%.

In general, following a 5-year period of COVID-related setbacks and subsequent recovery in TB services and epidemic trends, **2025 was a year characterized by stability or small improvements. The main exception was a sizeable reduction in international donor funding**. The TB response at global, regional and country levels has demonstrated considerable resilience in the face of external shocks.

Further and faster reductions in the burden of TB disease require improvements in the coverage of TB diagnostic, treatment and preventive interventions; action on broader determinants that drive new infections or increase the risk of developing disease once infected; and **technological breakthroughs, such as a new TB vaccine. All depend on adequate funding.**

Political commitment and domestic funding are critical to sustain and accelerate progress towards the goal of ending the global TB epidemic, especially in countries with the highest burden.

::::::::

WHO updates global catalogue for interpreting tuberculosis drug resistance mutations
10 November 2026 *Departmental update*
The World Health Organization (WHO) today published the third edition of the Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, providing **the most comprehensive global reference to date for interpreting genomic mutations associated with drug-resistant tuberculosis (TB).**

The updated catalogue strengthens the evidence base for molecular and sequencing-based drug resistance testing for TB, **supporting more consistent interpretation and use of genomic data across laboratories, surveillance programmes, diagnostic developers and researchers worldwide.**

"Rapid and accurate detection of drug resistance is essential to ensuring that people with tuberculosis receive the most effective treatment as early as possible," said Dr Tereza Kasaeva, Director of WHO's Department for HIV, TB, Hepatitis and Sexually Transmitted Infections. "As targeted next-generation sequencing technologies become increasingly accessible, this third edition substantially expands the global evidence available for interpreting drug resistance, including for newer and repurposed medicines, while strengthening guidance to support the consistent application of genomic results in practice."

The third edition has been updated to:
- include data from more than 71 000 clinical Mycobacterium tuberculosis isolates from over 75 countries – representing 37% and 12% increases in volume and coverage over the second edition that was published in 2023;
- expand evidence for newer and repurposed anti-TB medicines, including pretomanid and cycloserine;
- incorporate updated bioinformatic and statistical methods to improve mutation classification;
- introduce an enhanced interpretation framework in which the Graded Mutation List is applied together with additional grading rules and other interpretation criteria to support appropriate interpretation of drug resistance;
- provide strengthened practical guidance and new FAQs to support users in understanding, applying and implementing the catalogue; and
- strengthen support for sequencing-based drug susceptibility testing, the development and evaluation of molecular diagnostics, and global TB drug resistance surveillance…

::::::::

::::::::
::::::::

Ebola – Bundibugyo virus disease (BVD) – PHEIC/PHECS

WHO

Conflict and disease outbreaks deepen DR Congo's hunger crisis as record numbers are projected to face acute food insecurity
FAO, WFP, UNICEF and WHO call for urgent action as acute hunger is projected to hit more than 30 million, including 4.2 million people facing Emergency levels of hunger in early 2027
13 November 2026 *Joint News Release* Kinshasa/Rome/New York/Geneva

Severe hunger is expected to deepen in the Democratic Republic of the Congo (DRC), with a record 30.3 million people projected to face Crisis levels of acute food insecurity or worse (IPC Phase 3 or above) between January and June 2027, according to the latest Integrated Food Security Phase Classification (IPC) analysis.

Conflict, displacement and rising food prices are driving the crisis, compounded by Ebola – a severe and often fatal viral disease – and other disease outbreaks. Humanitarian assistance is now falling dangerously behind growing needs, warn the United Nations World Food Programme (WFP), the Food and Agriculture Organization of the United Nations (FAO), UNICEF and the World Health Organization (WHO).

Nearly 29 million people – almost a quarter of the population – face Crisis or worse levels of acute food insecurity (IPC Phase 3 or above) from September to December 2026, including 3.6 million in Emergency (IPC Phase 4). By early 2027, the number facing Emergency levels of hunger is projected to rise by nearly 600 000 to 4.2 million. The total facing Crisis or worse is projected to reach 30.3 million between January and June 2027, up from 26.5 million between January and June 2026…

::::::::

Africa

Africa CDC
Africa CDC Statement on the Attack in North Kivu, DRC
Press Releases 8 November 2026
The Africa Centres for Disease Control and Prevention (Africa CDC) strongly condemns the deadly attack on civilians in Cantine-Aloya, North Kivu, DRC, on 5 November 2026, reportedly carried out by the Allied Democratic Forces (ADF).
Africa CDC extends its deepest condolences to the families of those killed and expresses its solidarity with the injured, displaced and affected communities.
The attack comes at a critical moment in the response to the ongoing Ebola outbreak. Health facilities have been attacked and patients, including hundreds people with confirmed or suspected Ebola infection, have fled in search of safety raise serious public health concerns…

::::::::

UN System/Multilateral Institutions/Economic Development Alliances
[See joint news release above]

::::::::
::::::::

Regions / Nation States
No new digest content identified.

::::::::

INGOs, CSOs

MSF/Médecins Sans Frontières
DRC Ebola outbreaks
Ebola in DRC: Persistent gaps between resources and action remain six months on
Press Release 12 Nov 2026
GENEVA – Democratic Republic of the Congo (DRC), Médecins Sans Frontières (MSF) warns that the second largest Ebola outbreak on record remains out of control. A troubling disconnect between the considerable resources mobilised for the response and what is actually reaching patients, frontline workers, and communities continues. Urgent action is needed to ensure available resources translate into effective, coordinated activities where they are needed most…

DRC Ebola outbreaks
Broader use of ERVEBO® vaccine could help protect people from Bundibugyo Ebola outbreak today
Press Release 10 Nov 2026
- The Bundibugyo Ebola virus outbreak in Democratic Republic of Congo continues to claim lives.
- While development of virus-specific vaccines is underway, people at risk should be given broader access to the ERVEBO® vaccine.
- Merck, global health authorities, and partners must ensure that vaccine allocations can enable a meaningful expansion of vaccination.

::::::::
::::::::

Polio – PHEIC

Polio this week [04 October 2026]
Headlines [Selected]
:: **Eradicating polio takes more than vaccines – it takes political courage**
In a Tagesspiegel opinion piece, infectious disease expert and former German parliamentarian Prof. Andrew Ullmann calls for sustained political commitment and funding to finish the job. Read the article (in German).
:: **GPEI '3-2-1' High-level Interview: Alishba Khan Barech**
In the latest in a series of high-level interviews, UNICEF Polio Champion, youth advocate and author Alishba Khan Barech offers her views on what it will take to ensure no child will ever again be paralysed by poliovirus. Read the full interview.

Summary of new polioviruses this week:
:: Pakistan : one WPV1 case and three WPV1-positive environmental samples
:: Central African Republic (CAR): one cVDPV2-positive environmental sample
:: DR Congo : nine cVDPV2 cases
:: Nigeria : one cVDPV2 case and two cVDPV3 cases
:: South Sudan : one cVDPV1 case

::::::::

Statement of the Forty-sixth Meeting of the Polio IHR Emergency Committee
13 November 2026 *Statement*
[Excerpts]
The 46th meeting of the Emergency Committee under the International Health Regulations (IHR or Regulations) on the international spread of poliovirus was **convened by the WHO Director-General on 30 September 2026** via video conference with affected countries, supported by the WHO Secretariat.

The Emergency Committee reviewed the latest epidemiological data on wild poliovirus type 1 (WPV1) and circulating vaccine-derived polioviruses (cVDPV) in the context of the global targets to interrupt endemic WPV1 transmission in 2026 and to stop cVDPV2 outbreaks by 2028 with subsequent certification of WPV1 eradication and cVDPV2 elimination. **Technical updates were received about the situation in the following countries: Afghanistan, Central African Republic, Democratic Republic of Congo, Ethiopia, Pakistan, South Sudan, and Sudan…**

…Conclusion
[1] **The Committee unanimously concluded that the risk of international spread of polioviruses continues to constitute a Public Health Emergency of International Concern (PHEIC)** and recommended extending the Temporary Recommendations for a further three months.
[2] The Committee, after a thorough review of the epidemiological and programmatic situation, unanimously concluded that **the event does not constitute a pandemic emergency.**

In reaching the conclusion that the risk of international spread of poliovirus continues to constitute a PHEIC, the Committee considered the following factors:
:: Ongoing risk of WPV1 international spread…
:: Ongoing risk of cVDPV international spread…

Additional considerations and recommendations
…**The Committee noted that the risk of international spread of WPV1 remains significant due to ongoing transmission in the two endemic countries, Afghanistan and Pakistan.**

Similarly, the risk of international spread of cVDPV2 remains significant due to intense transmission in parts of the African Region. Ongoing population movements, including across international borders, contribute to the risk of international spread of both WPV1 and cVDPV2. Though the risk of international spread remains considerably lower for circulating vaccine-derived poliovirus types 1 and 3 (cVDPV1 and cVDPV3) than for cVDPV2, the increase in the number of cVDPV1 and cVDPV3 cases in 2026 is concerning, indicating the presence of population subgroups with suboptimal immunity to poliovirus types 1 and 3 and underscoring the importance of improving routine immunization. The Committee recommended the implementation of high-quality outbreak response measures to stop the cVDPV1 and cVDPV3 outbreaks and prevent further geographic spread.

The Committee noted that, given the ongoing financial constraints facing the GPEI, preventive vaccination campaigns using bOPV cannot be financially supported in countries without active transmission of poliovirus type 1 or type 3. The Committee encouraged countries where population immunity to types 1 and/or 3 is very low to consider conducting catch-up vaccination activities through routine immunization programmes and, where justified by a careful risk assessment, conducting supplementary immunization activities with bOPV using domestic resources.

Based on the current situation regarding WPV1 and cVDPVs, and the reports provided by affected countries, the Director-General accepted the Committee's assessment, and on 12 November 2026 determined that the poliovirus situation continues to constitute a public health emergency of international concern (PHEIC) with respect to WPV1 and cVDPV. He further followed the advice of the Committee that the poliovirus situation does not constitute a pandemic emergency.

The Director-General endorsed the Committee's recommendations for countries meeting the definition for 'States infected with WPV1, cVDPV1 or cVDPV3', 'States infected with cVDPV2' and for 'States previously infected by WPV1 or cVDPV within the last 24 months' and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of polioviruses, effective, 12 November 2026.

::::::::

Syrian Arab Republic launches coordinated public health response following poliovirus detection in Deir Ezzor
9 November 2026, Damascus, Syrian Arab Republic – The Ministry of Health is strengthening vaccination and surveillance activities to protect children **following the detection of poliovirus type 1 (VDPV1) in two children aged between 6 and 13 months who developed paralysis in Deir Ezzor Governorate.**

The Ministry, supported by the World Health Organization (WHO), the United Nations Children's Fund (UNICEF) and other partners, has already **begun vaccination activities in affected areas and is preparing further campaigns.** Families are encouraged to check their children's vaccination records, complete all recommended doses and participate in campaigns targeting their children…

Disruptions to health services and difficulties accessing routine immunization have left gaps in protection in some communities. **The response focuses on reaching children who have missed vaccinations and on helping families access reliable information and essential health services.**

Following initial reports of suspected cases on 11 October 2026, health teams conducted a vaccination campaign on 18 October, reaching more than 34 000 children under five in affected areas of Deir Ezzor.

A further campaign is planned for next week, with additional rounds and locations to be determined through ongoing assessments…

The Ministry, with support from WHO, UNICEF and partners, is strengthening surveillance and conducting field investigations to identify any further cases, assess the risk of transmission and guide vaccination activities.

::::::::
::::::::

Contents [click to move among sections]
:: Milestones, Perspectives
:: WHO
:: U.S. Immunization and Public Health Governance/Policy/Funding
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

:: Think Tanks
:: Public Consultations/Call for Inputs/Call for Papers

::::::::
::::::::

WHO & Regional Offices [14 Nov 2026]
https://www.who.int/news
Selected News/Announcements/Statements
13 November 2026 *Departmental update*
Put health in the treaty": youth delegates at the Global Model WHO 2026 adopt declaration on plastics and health

13 November 2026 *News release*
Member States reiterate commitment to finalize Pandemic Agreement PABS Annex by May 2027

13 November 2026 *Statement*
Statement of the Forty-sixth Meeting of the Polio IHR Emergency Committee

13 November 2026 *Joint News Release*
Conflict and disease outbreaks deepen DR Congo's hunger crisis as record numbers are projected to face acute food insecurity

12 November 2026 *News release*
Amid challenges, countries increase domestic investment to protect progress against tuberculosis

10 November 2026 *Departmental update*
WHO and African Medicines Agency advance regulatory cooperation at inaugural Agency Week in Kigali

10 November 2026 *News release*
WHO launches "Together for Science and Health" movement to strengthen trust worldwide

10 November 2026 *Departmental update*
From commitments to implementation: ATACH Day at COP31 delivers practical solutions for climate and health

10 November 2026 *Departmental update*
WHO updates global catalogue for interpreting tuberculosis drug resistance mutations

10 November 2026 *Departmental update*
WHO training strengthens global capacity for healthier, more equitable cities

10 November 2026 *Departmental update*
WHO releases global mega-map on age-friendly environments

9 November 2026 *Departmental update*
New WHO policy options call for stronger integration of health and care workforce

::::::::

WHO: GHA – Global Health Architecture

Reforming the global health architecture
WHO webpage for the GHA initiative
[Last update posted 26 June 2026]

::::::::

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1
News
No new digest content identified.

::::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO
:: 12 November 2026 | *News Release*
African health leaders adopt Nairobi Action Agenda to turn health data into better healthcare
:: 10 November 2026 | *News Release*
New WHO report reveals critical gaps in Africa's health information systems

WHO Region of the Americas PAHO
:: 13 Nov 2026
Public university hospitals in the Americas to develop regional alliance to strengthen health systems
The Brasília Charter marks a first step toward creating a regional alliance, setting out shared priorities for cooperation in hospital management, research, workforce development and emergency preparedness. Brasília, Brazil, 13 November 2026 (PAHO) – Representatives of public university hospitals and health authorities from across the Americas are…
:: 12 Nov 2026
Diabetes in the Americas: 112 million adults live with the disease as gaps in diagnosis and treatment persist
More than 4 in 10 people living with diabetes worldwide are unaware they have the condition. Ahead of World Diabetes Day, PAHO calls for stronger early detection and primary health care, as well as measures to prevent or delay type 2 diabetes and its complications. Washington, D.C., 12 November, 2026 (PAHO) – In the Region of the Americas, 112…
::
11 Nov 2026
PAHO secures first-ever region-wide access agreements for HPV testing across Latin America and the Caribbean, with support from Unitaid
Landmark regional agreements will lower costs of high-quality HPV testing and help more women benefit from effective cervical cancer screening. Washington, D.C./Geneva, 11 November 2026 — Millions of women across Latin America and the Caribbean will gain access to more affordable, high-quality human papillomavirus (HPV) testing under landmark…

WHO South-East Asia Region SEARO
:: 13 November 2026 *News release*
WHO calls for stronger multisectoral action to end TB in South-East Asia Region

WHO European Region EURO
:: 10 November 2026 *News*
WHO/Europe launches new platform to improve access to new and innovative medicines
WHO has launched the European Access Dialogue Platform (EADP) – a new dialogue platform for open, structured and inclusive discussion across the lifecycle of new and innovative so called "novel" medicines.

WHO Eastern Mediterranean Region EMRO
:: **Syrian Arab Republic launches coordinated public health response following poliovirus detection in Deir Ezzor**
9 November 2026

WHO Western Pacific Region
No new digest content identified.

::::::

WHO - Emergency situation reports
Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.
No new digest content identified.

::::::::

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health Disease Outbreak News
13 November 2026 | Middle East respiratory syndrome (MERS) – Qatar

:::::::

Weekly Epidemiological Record
https://www.who.int/publications/journals/weekly-epidemiological-record
Volume 101 Issue 45 Epidemiological Week 45 (2 November – 8 November 2026)
https://www.who.int/publications/journals/weekly-epidemiological-record/wer101-42
- Highlighted signals and events
- Schistosomiasis and soil-transmitted helminthiases: progress report, 2025

:::::::

New WHO Publications
https://www.who.int/publications
Selected
13 November 2026
2025 WHO health and climate change global survey report
Overview
The 2025 WHO Health and Climate Change Global Survey report provides a global assessment of country-level progress in addressing the health impacts of climate change and developing climate-resilient and low-carbon health systems. Drawing on responses from 146 countries, this edition expands the scope of previous surveys and establishes a baseline for monitoring the WHO Global Action Plan on Climate Change and Health and the climate-related outcomes of WHO's Fourteenth General Programme of Work.

The findings indicate that national governance structures, vulnerability and adaptation assessments, and climate and health planning have expanded, but implementation remains limited. More than 90% of countries have designated climate and health focal points, while over half have national strategies or health adaptation plans. However, insufficient financing, limited workforce capacity and inadequate monitoring continue to constrain progress. The transition towards low-carbon and sustainable health systems remains at an early stage, with persistent inequalities affecting lower-income countries. The report highlights the need to strengthen implementation, expand access to financing and build health system resilience.
:: WHO's work on climate change and health
:: WHO's work on environment, climate change, one health and migration

12 November 2026
Global tuberculosis report 2026

::::::::
::::::::
::::::::

Africa

Africa CDC [14 Nov 2026]
https://africacdc.org/
News & Updates [Selected]
AFRICA CDC WELCOMES THE APPOINTMENT OF DR MARK DYBUL AS EXECUTIVE DIRECTOR OF THE GLOBAL FUND AND CALLS FOR A NEW ERA OF AFRICAN OWNERSHIP AND HEALTH SOVEREIGNTY
9 November 2026

Press Releases
Africa CDC Statement on the Attack in North Kivu, DRC
8 November 2026
The Africa Centres for Disease Control and Prevention (Africa CDC) strongly condemns the deadly attack on civilians in Cantine-Aloya, North Kivu, DRC, on 5 November 2026, reportedly carried out by the Allied Democratic Forces (ADF).
Africa CDC extends its deepest condolences to the families of those killed and expresses its solidarity with the injured, displaced and affected communities.
The attack comes at a critical moment in the response to the ongoing Ebola outbreak. Health facilities have been attacked and patients, including hundreds people with confirmed or suspected Ebola infection, have fled in search of safety raise serious public health concerns…

African Medicines Agency [14 Nov 2026]
https://au-ama.africa/news-events/
Latest News & Events
No new digest content identified.

::::::
::::::

China – CDC+

National Health Commission of the People's Republic of China [14 Nov 2026]
http://en.nhc.gov.cn/

News
No new digest content identified.

National Medical Products Administration – PRC [14 Nov 2026]
https://english.nmpa.gov.cn/
Website not responding at inquiry.

China CDC
***CCDC Weekly Reports*: Current Volume (8)**
2026 Vol. 8 No. 46 PDF
https://weekly.chinacdc.cn/article/current
No new digest content identified.

::::::
::::::

Europe

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
News/Updates/Reports/Publications [Selected]
Preparations continue for rollout of new public health surveillance platform in nine pilot countries
11 November 2026
Next year's rollout of Epi+, a multilingual event-based surveillance platform designed to help countries detect and assess emerging public health threats, is coming closer as the European Centre for Disease Prevention and Control (ECDC) and Italy's Istituto Superiore di Sanità (ISS) hold training this week for 40 national epidemiologists and technical experts in Rome.

Surveillance and monitoring
Seasonal surveillance of dengue in the EU/EEA
13 November 2026

Surveillance and monitoring
Seasonal surveillance for chikungunya virus disease in the EU/EEA for 2026
13 November 2026

Surveillance and monitoring
Surveillance of Mpox in the EU/EEA, monthly report
13 November 2026

European Medicines Agency [EMA]
https://www.ema.europa.eu/en/news
News & Press Releases
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026
Seven new medicines recommended for approval; another 11 medicines recommended for extension of their therapeutic indications
13 November 2026

::::::::

::::::::

India

National Centre for Disease Control
Directorate General of Health Services, Ministry of Health & Family Welfare
Announcements
No new digest content identified.

Indian Council of Medical Research (ICMR)
Press Releases
No new digest content identified.

Ministry of Health and Family Welfare
Press Releases
No new digest content identified.

::::::::
::::::::
::::::::

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive

Executive Branch - White House, State, HHS, FDA, CDC+

White House
Presidential Actions – Executive Orders; Memoranda; Proclamations
No new digest content identified.

Department of State
Press Releases - Selected
No new digest content identified.

HHS
Press Room - Selected
No new digest content identified.

NIH
News Releases
No new digest content identified.

FDA
Press Announcements
No new digest content identified.

FDA CBER
What's New for Biologics
No new digest content identified.

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]
Advisory Committee Calendar
No new committee meeting announcements identified.

FDA Pediatric Advisory Committee Meeting
Advisory Committee Calendar
No new committee meeting announcements identified.

CDC
http://www.cdc.gov/media/index.html
Latest News - Selected
No new digest content identified.

> ***Editor's Note:***
> A number of media outlets are reporting that the **U.S. will formally lose its measles elimination status when PAHO's Measles and Rubella Elimination Regional Monitoring and Re-Verification Commission meets next week.**
> Please see our coverage of statements issued in advance of that formal announcement from U.S. Medical, Scientific, Professional Societies; Health Organizations below, as well as KFF's analysis. We will provide full coverage of the PAHO Commission's announcement in next week's edition.

CDC – Immunization Safety Office (ISO)
https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html
No new digest content identified [last updated August 7, 2024]

ACIP
2026 Meetings Schedule *[as posted]*
- March 18-19 (Due to ongoing litigation, this meeting is cancelled)
- June 24-26 (Due to ongoing litigation, this meeting is cancelled)
- October 21-23 (Due to ongoing litigation, this meeting is cancelled)

Solicitation of Nominations for Appointment to the Advisory Committee on Immunization Practices
A Notice by the Centers for Disease Control and Prevention on 10/30/2026
SUMMARY:
In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is seeking nominations for membership on the Advisory Committee on Immunization Practices (ACIP). The ACIP consists of up to 19 experts that collectively represent a balanced range of scientific, clinical, and public health expertise relevant to the Committee's mission, including person(s) knowledgeable about consumer perspectives and/or social and community aspects of immunization programs.
DATES:
Nominations for membership on the ACIP must be received no later than December 31, 2026. Submissions received after this time will not be considered for the current membership cycle.

National Vaccine Advisory Committee (NVAC)
https://www.hhs.gov/programs/national-vaccine-program/nvac/index.html
Upcoming Meetings/Latest Updates
No new meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)
https://www.hrsa.gov/advisory-committees/vaccines/meetings
Next ACCV meetings – TBD

MMWR Weekly
https://www.cdc.gov/mmwr/index2026.html
November 12, 2026 / No. 44
PDF of this issue
:: *Notes from the Field:* Dengue Outbreak — American Samoa, 2025–2026

::::::::

National Science Foundation/NSF
News
No new digest content identified.

::::::::

U.S. Congress

House
No new digest content identified.

Senate
No new digest content identified.

::::::::

Supreme Court, Federal & Appellate Courts

O'Neill Institute – Health Care Litigation Tracker [Georgetown University]
https://litigationtracker.law.georgetown.edu/
No new digest content identified.

::::::::
::::::::
::::::::

U.S. Medical, Scientific, Professional Societies; Health Organizations

This inventory is evolving and may not capture all instances of relevant comment and analysis.

American Academy of Family Physicians (AAFP)
https://www.aafp.org/news/media-center.html
(Accessed 14 Nov 2026)
Family Physicians: We Must Use Every Available Lever to Stop Ongoing Measles Transmission
November 14, 2026

The loss of measles elimination status in the U.S. is a dangerous and serious step backward for public health. It signals that the virus is spreading continuously and that too many people remain unprotected. It does not mean the MMR vaccine has stopped working. It means we must restore confidence in the safety and efficacy of life-saving public health tools.

Measles is not harmless. It is highly contagious, and infants, children, older adults, pregnant patients and people with underlying health conditions all face serious risks. We cannot gamble with our nation's health. Even small outbreaks can cost millions to contain, and every hour and resource spent responding to measles outbreaks is time taken from other urgent community health needs.

The good news is that these outbreaks are entirely preventable**. The science has not changed—the MMR vaccine is our best protection against measles. It is safe and effective, and two doses are about 97% effective at preventing the disease.**

A drop in cases alone will not return measles to the history books. Restoring elimination status requires an organized and sustained response that includes increased support for state and local health departments, timelier surveillance and communications, clear information for families and an easier path to vaccination. **We must use every available lever to stop ongoing transmission and rebuild a community of immunity.**

American Academy of Pediatrics (AAP)
https://www.aap.org/en/news-room/news-releases-from-the-aap/
(Accessed 14 Nov 2026)
News
No new digest content identified.

American College of Physicians (ACP)
https://www.acponline.org/more-acp-news
(Accessed 14 Nov 2026)
No new digest content identified.

America's Health Insurance Plans (AHIP)
https://www.ahip.org/news
(Accessed 14 Nov 2026)
News
No new digest content identified.

American Geriatrics Society (AGS)
https://www.americangeriatrics.org/media-center
(Accessed 14 Nov 2026)
Recent Press Releases
No new digest content identified.

American Medical Association (AMA)
https://www.ama-assn.org/press-center
(Accessed 14 Nov 2026)
Press Releases
No new digest content identified.

American Osteopathic Association (AOA)
https://osteopathic.org/news/
(Accessed 14 Nov 2026)
Latest News

No new digest content identified.

American Public Health Association (APHA)
https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc
(Accessed 14 Nov 2026)
The Loss of Measles Elimination Status in the U.S. Amidst A Deadly Outbreak Should Have Been Prevented
November 13, 2026

Amid vaccine disinformation and the deaths of Americans who had measles, it is no surprise that news reports say the U.S. has lost its elimination status ahead of an official Pan American Health Organization announcement, all while a deadly outbreak continues to sicken people across the nation. A national call to vaccinate to slow the spread of the infectious disease, especially as outbreaks emerged in 2025, would have prevented this. Instead of choosing to take such preventative measures to keep communities healthy and maintain the nation's elimination status, HHS leadership allowed unscientific ideas and talking points to guide important decision-making, leading to a web of confusion and heartbreaking loss. If communities can no longer count on HHS leadership to put forth evidence-based guidance to promptly respond to the ongoing outbreak, we will see more kids missing school, along with unnecessary hospitalizations and deaths.

We urge all families and community members to reach out to doctors and state and local health departments about the facts of vaccination and what measles does to the immune system. Decades of research already show the effectiveness of immunization in minimizing serious complications and preventing death. T**o lose elimination status in such a short window should serve as a stark warning that this outbreak cannot be ignored or treated as an unfortunate life event.**

Infectious Diseases Society of America (IDSA)
https://www.idsociety.org/
(Accessed 14 Nov 2026)
News
U.S. loss of measles elimination status would be a major public health setback
Last Updated November 12, 2026

The Pan American Health Organization's expected removal of the U.S. measles elimination status will mean decades of public health gains have been officially reversed. For nearly 30 years, the measles virus posed little threat in the United States because of strong public health leadership and trust in science. The reemergence of measles at dangerous levels has quickly become a threat to communities across the country.

The expected loss of America's status as having eradicated measles will be a tragedy because it reflects the preventable loss of human lives**. It is unthinkable that people in the United States should be dying from measles in 2026.** There have been eight reported deaths this year and more than 5,000 confirmed cases, when just a few years ago there were nearly none. **Perhaps most heartbreaking is the potential long-term toll on infants infected this year, some of whom may develop fatal neurologic disease years after the initial infection.**

This expected reversal of America's status is a reminder that infectious diseases have serious consequences. **Our government's leaders and public health officials must heed this urgent warning and take actions that slow the spread. That starts with promoting vaccination against measles, which is proven to be safe and effective**.

In addition, government leaders should work closely with PAHO to reestablish measles elimination, sufficiently fund state and local health departments to support community-level containment efforts, and invest in the infectious diseases workforce necessary to prevent, diagnose, treat and contain vaccine-preventable diseases, including measles.

The lives of people in the United States are at risk. It's time to act like it.
— Wendy S. Armstrong, MD, FIDSA — President, IDSA

National Foundation for Infectious Diseases (NFID)
https://www.nfid.org/news-updates/
(Accessed 14 Nov 2026)
News and Updates
November 14, 2026
Measles Collaborative Statement on US Measles Elimination Status

The reported loss of US measles elimination status is a significant public health setback. It underscores the urgent need to strengthen measles prevention and response. **The priority is clear: raise immunization rates to at least 95% to protect communities and prevent further spread**. This means investing in long-term relationships, listening to and engaging with communities, and building the trust to help families understand how to protect against disease.

"This is a critical moment to refocus our efforts on what we know works: vaccination. While measles is highly contagious, it is also preventable. We need to work together to ensure more people are protected, help families understand the importance of MMR vaccination, and equip healthcare professionals and public health teams to respond quickly to individual cases and outbreaks," said Patsy Stinchfield, Executive Director of the Measles Collaborative.

The Measles Collaborative, an initiative of the National Foundation for Infectious Diseases (NFID), brings together expertise from across the public health and healthcare communities to strengthen measles prevention and response. We remain committed to advancing evidence-based information, supporting healthcare professionals and public health partners, building trust, and increasing vaccination coverage to protect individuals and prevent further transmission.

For more information on the Pan American Health Organization (PAHO) decision, visit: Measles and Rubella Elimination Regional Monitoring and Re-Verification Commission

November 14, 2026
NFID Statement on US Measles Elimination Status

The reported loss of measles elimination status in the US is a significant setback for public health, reflecting sustained transmission and persistent gaps in vaccination coverage. The National Foundation for Infectious Diseases (NFID) urges coordinated action to interrupt measles transmission and raise measles, mumps, rubella (MMR) vaccination coverage to at least 95% in schools, healthcare settings, and communities nationwide. High vaccination coverage is essential to preventing outbreaks, protecting vulnerable populations, and reducing measles-related illness and death.

Before the measles vaccine became available in 1963, an estimated 3 to 4 million people in the US were infected and 400-500 died each year.[1] Although many people recover from measles, it can cause serious illness, particularly in young children. About 1 in 5 unvaccinated people in the US who get measles are hospitalized, and 1 to 3 of every 1,000 children with measles die, even with the best care.[2]

Widespread vaccination dramatically reduced cases and deaths, and measles was declared eliminated in the US in 2000. **In recent years, the conditions that made elimination possible have eroded. National MMR vaccination coverage among kindergarteners has fallen below the critical 95% threshold needed for community protection, and coverage is well below 90% in some communities.**

After experiencing 285 reported measles cases in 2024, the US reported 2,289 cases in 2025. As of November 13, 2026 at least 5,412 confirmed measles cases and 10 deaths have been reported in the US this year. About 96% of cases occurred in people who were unvaccinated or whose vaccination status was unknown. Cases have also been reported among pregnant women, increasing the risk of

severe illness in the mother and of complications such as miscarriage, stillbirth, preterm birth, and low birth weight.

Elimination is an important milestone, but the ultimate priority is preventing measles illness and death. To achieve this goal, the US must:

- Increase MMR vaccination coverage to at least 95% in communities nationwide.
- Identify and address gaps and barriers in vaccination coverage, particularly in communities experiencing outbreaks or at increased risk of transmission.
- Strengthen timely case identification, diagnosis, reporting, contact tracing, and outbreak response.
- Equip healthcare professionals and public health officials with trusted guidance and practical resources.
- Provide clear, credible information that addresses questions about measles and vaccination and helps people make informed decisions.
- Coordinate efforts across healthcare, public health, academic, and professional organizations to interrupt transmission and support the path toward regaining elimination status.

"Measles elimination was a hard-won victory; restoring that status is achievable and should be a major public health priority," said Robert H. Hopkins, Jr., MD, NFID Medical Director. "Two doses of MMR vaccine are about 97% effective at preventing measles. Closing vaccination gaps is the most important step we can take to protect communities and regain elimination status. As measles continues to challenge public health, NFID remains committed to working with partners in the Measles Collaborative to share expertise, coordinate communications, and support timely response."

[1] History of measles. Centers for Disease Control and Prevention. Updated April 29, 2026. Accessed November 14, 2026. https://www.cdc.gov/measles/about/history.html(opens in new tab)

[2] Measles symptoms and complications. Centers for Disease Control and Prevention. Updated August 5, 2026. Accessed November 14, 2026. https://www.cdc.gov/measles/signs-symptoms/index.html

National Medical Association (NMA)
https://nmanet.org/blog/
(Accessed 14 Nov 2026)
Latest News
No new digest content identified.

Pediatric Infectious Diseases Society (PIDS)
https://pids.org/news-announcements/
(Accessed 14 Nov 2026)
News & Announcements
No new digest content identified.

Society for Healthcare Epidemiology of America (SHEA)
https://shea-online.org/news/
(Accessed 14 Nov 2026)
No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)
https://www.smfm.org/
(Accessed 14 Nov 2026)

News
No new digest content identified.

::::::::
::::::::

Civil Society – Individuals, Organizations, Institutions *[Selected]*

::::::::

Kaiser Family Foundation/KFF [14 Nov 2026]
https://www.kff.org/search/?post_type=press-release
Research, Analysis
Measles Elimination Status: What It Is and How the U.S. Could Lose It
Nov 13, 2026 *Policy Watch*
This policy watch examines the United States' measles elimination status, including what it means to eliminate measles, whether the current measles outbreak could threaten the country's measles elimination status, and what losing that status might mean for measles control.

A Step Back for U.S. Public Health: The U.S. Is Likely to Lose Its Measles Elimination Status
Nov 13, 2026 *Quick Insights*
The loss of measles elimination status would primarily carry symbolic weight, as the effect of rising cases and deaths is already clear. Still, it is a marker of how a combination of factors - COVID-19, increasing vaccine skepticism, and a growing partisan divide about vaccines - has been a step back for public health, and it is not clear when or if this trend will be reversed.

::::::::

Vaccine Integrity Project – CIDRAP [to 14 Nov 2026]
https://www.cidrap.umn.edu/vaccine-integrity-project
Announcements, Viewpoints
No new digest content identified.

::::::::

Center for Vaccine Ethics & Policy - GE2P2 Global Foundation [to 14 Nov 2026]
https://centerforvaccineethicsandpolicy.net/
No new digest content identified.

::::::::

Paul Offit, MD – *Beyond the Noise*
Substack: https://pauloffit.substack.com/
RFK Jr.'s Thalidomide Gambit
RFK Jr. has transformed the medical freedom movement into freedom from federal regulation of foods, biologicals, vaccines, and drugs.
Nov 09, 2026

::::::
::::::

Contents [click to move among sections]
:: *Milestones, Perspectives*
:: *WHO*
:: *Organization Announcements*
:: *Journal Watch*
:: *Pre-Print Servers*

::::::
::::::

Organization Announcements

Paul G. Allen Frontiers Group [14 Nov 2026]
https://alleninstitute.org/news-press/
News
No new digest content identified.

Gates Foundation [14 Nov 2026]
https://www.gatesfoundation.org/ideas/media-center
Press Releases & Statements
Flagship Pioneering and Gates Foundation Launch Collaboration to Accelerate Advancement in Global Health and Development to Benefit Underserved Populations
Joint funding up to $25 million to identify and evaluate programs focused on global health, women's health, and agriculture
SEATTLE & CAMBRIDGE, MASS (November 12, 2026) – Flagship Pioneering, a scientific innovation engine for transformative platforms and products and the Gates Foundation, today announced a collaboration to fund the discovery of potential breakthrough health and agricultural solutions to benefit underserved populations in low- and middle-income countries…

CARB-X [14 Nov 2026]
https://carb-x.org/
News
11.12.2026 |
CARB-X funds UNSW Sydney to develop novel antibiotic targeting drug-resistant Gram-negative bacterial infections
CARB-X is awarding US$853k to UNSW Sydney to support the development of synthetic darobactin analogues, a new class of antibiotic designed to kill multidrug-resistant Gram-negative bacteria.

Chan Zuckerberg Initiative [14 Nov 2026]
https://chanzuckerberg.com/newsroom/
Newsroom
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [14 Nov 2026]
http://cepi.net/
News
No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 14 Nov 2026]
https://cioms.ch/
News; Publications; Events
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [14 Nov 2026]
https://www.darpa.mil/news
News
No new digest content identified.

DNDI – Drugs for Neglected Diseases Initiative [14 Nov 2026]
https://dndi.org/press/press-releases/
Press Releases
No new digest content identified.

Duke Global Health Innovation Center [14 Nov 2026]
https://dukeghic.org/
News
No new digest content identified.

EDCTP [14 Nov 2026]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
No new digest content identified.

Emory Vaccine Center [14 Nov 2026]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [14 Nov 2026]
http://www.euvaccine.eu/
News
No new digest content identified.

Fondation Merieux [14 Nov 2026]
http://www.fondation-merieux.org/
Actualités
No new digest content identified.

Gates Medical Research Institute [14 Nov 2026]
https://www.gatesmri.org/news
News: Articles and Publications
PAN-TB Collaboration to Launch New Clinical Trial of Next-Generation Tuberculosis Treatment Regimen
November 10, 2026•Press Release
Phase 2 trial will evaluate new investigational "pan-TB" regimen that includes three new compounds, in pursuit of a shorter, simpler TB treatment.

Gavi [to 14 Nov 2026]
https://www.gavi.org/
News Releases [Selected]
11 November 2026
Health facility solarisation drive unlocks benefits for over 140 million people in underserved communities in Africa and Asia
Geneva, 11 November 2026 – An ambitious drive to solarize primary health care facilities, backed by an investment of more than US$30 million from Gavi, the Vaccine Alliance, is helping unlock benefits for more than 140 million people in underserved communities across Africa and Asia. By solarizing more than 1,700 facilities across Ethiopia, Nigeria, Pakistan, Uganda and Zambia, the initiative is helping address one of the most persistent barriers to equitable immunisation – unreliable access to electricity at frontline health facilities – while making long-term investments in health care service delivery…

10 November 2026
Cambodia accelerates cervical cancer prevention through HPV Multi-Age-Cohort Vaccination Campaign for adolescent girls
Phnom Penh, 10 November 2026 – The Royal Government of Cambodia, through the Ministry of Health and the National Immunization Programme (NIP), today launched a nationwide Human Papillomavirus (HPV) Multi-Age Cohort (MAC) vaccination campaign, which vaccinates multiple age groups of adolescent girls at the same time, and catch-up vaccination, expanding protection against cervical cancer for adolescent girls across the country…

GE2P2 Global Foundation [14 Nov 2026]
www.ge2p2.org
News/Analysis/Publications-Digests/Statements/Digests
:: **The Sentinel** *– Health :: Human Rights :: Humanitarian Action :: Peace :: Heritage/Literacy/Education :: Climate :: Sustainable Development* - Current edition

GHIT Fund [14 Nov 2026]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified.

Global Fund [to 14 Nov 2026]
https://www.theglobalfund.org/en/news/
News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [14 Nov 2026]
https://www.glopid-r.org/
News & Event
GloPID-R convenes roundtable to strengthen social and behavioural sciences evidence for Ebola Bundibugyo response
16/06/2026

Hilleman Laboratories [14 Nov 2026]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [14 Nov 2026]
https://www.hhmi.org/news
News & Stories
No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [14 Nov 2026]
https://www.humanimmunomeproject.org/
News
No new digest content identified.

IAVI [14 Nov 2026]
https://www.iavi.org/
Press Releases, Features
No new digest content identified.

INSERM [14 Nov 2026]
https://www.inserm.fr/en/home/
Press Releases
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 14 Nov 2026]
https://www.ich.org/page/public-consultations
News/Pubs/Press Releases [Selected]

No new digest content identified.

ICRC [to 14 Nov 2026]
https://www.icrc.org/en/news
Latest press releases and statements
ICRC president: States must act to ensure the future of warfare is not handed over to machines
Statement 13-11-2026

IFFIm [14 Nov 2026]
http://www.iffim.org/
No new digest content identified.

IFRC [to 14 Nov 2026]
http://media.ifrc.org/ifrc/news/press-releases/
Press releases
No new digest content identified.

IPPS - International Pandemic Preparedness Secretariat [14 Nov 2026]
https://ippsecretariat.org/news/
News
Registration now open: 100 Days Mission Report Launch and IPPS Transition Event
October 20, 2026
Hybrid Event | Wednesday 3rd February 2027 | London and online
Register here

Institut Pasteur [14 Nov 2026]
https://www.pasteur.fr/en/press-area
Press Documents
Press Release November 12, 2026
Andes hantavirus: characterization of a rare disease cluster by coordinated genomic sequencing

InterAcademy Partnership (IAP)
https://www.interacademies.org/news/press-releases
News
No new digest content identified.

ISC / International Science Council [to 14 Nov 2026]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations *including Academies and Research Councils.*
News, Blogs
Scientists from more than 45 countries call for a stronger voice for science as a global public

good
Released on World Science Day for Peace and Development, the 2026 Appeal for Science brings together researchers, presidents of national academies of sciences, Nobel laureates and other science leaders from every world region in a shared call to support science's contribution to human and planetary wellbeing.
[Undated]
Signatories from more than 45 countries across Africa, the Americas, Asia, Europe and Oceania have endorsed the *Appeal to strengthen the voice of science as a global public good*, published today to mark World Science Day for Peace and Development…

Science academies from G20 nations identify opportunities for their governments to use advanced technology to strengthen disaster resilience
WASHINGTON — Today, the science academies of the G20 countries under the leadership of the U.S. National Academy of Sciences released a joint "S20" statement to inform discussions within the respective governments on how advanced technologies can be used to strengthen preparedness and response to natural hazards and disasters. The statement will be presented to the G20 prior to the summit to be held in Miami, Florida in December…

International Union of Immunological Societies (IUIS)
https://iuis.org/
News, Resources
No new digest content identified.

IVAC [14 Nov 2026]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI [14 Nov 2026]
http://www.ivi.int/
IVI News & Announcements
International Vaccine Institute adopts 2027–2031 Strategy to advance vaccine innovation and strengthen global health impact
New five-year strategy builds on the international organization's end-to-end R&D engine and focuses on prevention innovations, outbreak preparedness, and regional vaccine capabilities
12 November 2026

International Vaccine Institute secures seed funding from Coefficient Giving to establish BRIGHT Fund for global health innovation
The funding will support the establishment of a multi-donor financing platform to accelerate collaborative health innovation, strengthen research and development capabilities, and expand equitable access to life-saving technologies.
9 November 2026

Johns Hopkins Center for Health Security [14 Nov 2026]
https://centerforhealthsecurity.org/newsroom
Center News [Selected]
No new digest content identified.

Robert Wood Johnson Foundation [to 14 Nov 2026]
https://www.rwjf.org/en/about-rwjf/newsroom.html
Latest News and Highlights
No new digest content identified.

MSF/Médecins Sans Frontières [to 14 Nov 2026]
http://www.msf.org/
Latest [Selected Announcements]
Nigeria
Shortages of diphtheria treatment put thousands of children at risk in Nigeria
Press Release 13 Nov 2026

Abuja — Médecins Sans Frontières (MSF) warns that shortages of diphtheria antitoxin (DAT) – the critical drug for treating diphtheria – together with low immunisation coverage, are fuelling transmission of the disease and undermining efforts to control the outbreak in northern Nigeria. This puts thousands of children at risk of severe illness and death.

To save lives and help contain the outbreak, MSF urges federal and state authorities, donors, and international partners to urgently secure existing supplies of DAT, vaccines, and other essential medicines. Timely clearance at ports of entry and rapid distribution across affected areas in northern Nigeria must also be ensured.

"The global shortage of diphtheria antitoxin is becoming a matter of life and death," says Dr David Kizito, MSF medical coordinator in Nigeria. "Our stocks are dangerously low, and we risk being unable to treat children and save lives as the outbreak continues."…

Gaza-Israel war
MSF condemns another deadly attack on Nasser hospital
Statement 12 Nov 2026

Iraq
Mosul's nine years of healing
Project Update 12 Nov 2026

DRC Ebola outbreaks
Ebola in DRC: Persistent gaps between resources and action remain six months on
Press Release 12 Nov 2026

DRC Ebola outbreaks
Ebola disease: Behind the mask
Voices from the Field 11 Nov 2026

DRC Ebola outbreaks
Broader use of ERVEBO® vaccine could help protect people from Bundibugyo Ebola outbreak today
Press Release 10 Nov 2026

National Academy of Medicine - USA [to 14 Nov 2026]
https://nam.edu/programs/
News, Stories, Insights
Nov 6, 2026 News
Global Coalition of Academies of Medicine Convenes to Advance Climate and Health

Priorities Ahead of COP31

National Academies-Sciences-Engineering-Medicine [NASEM] - USA [to 14 Nov 2026]
https://www.nationalacademies.org/newsroom
News
Refugees Make Substantial Progress Toward Integration, Despite Initial Challenges, Says New Report
News Release Last update November 12, 2026
By Solomon Self

Science Academies from G20 Nations Identify Opportunities for Their Governments to Use Advanced Technology to Strengthen Disaster Resilience
Publish Date: November 10, 2026
WASHINGTON — Today, science academies from the G20 countries under the leadership of the U.S. National Academy of Sciences released a joint statement to inform discussions within their respective governments on how advanced technologies can be used to strengthen preparedness and response to natural hazards and disasters. The statement will be presented to the G20 prior to the summit to be held in Miami, Florida, in December.

PATH [14 Nov 2026]
https://www.path.org/media-center/
Newsroom [Selected]
No new digest content identified.

Rockefeller Foundation [to 14 Nov 2026]
https://www.rockefellerfoundation.org/
News and Announcements
Climate and Health Funders Coalition Awards $225 Million in First Year To Accelerate Solutions That Will Improve Health and Save Lives
Press Releases
Antalya, Türkiye | November 9, 2026 — The Climate and Health Funders Coalition has awarded more than $225 million in its first year, putting three-quarters of the initial $300 million pledged towards accelerating solutions on extreme heat, air pollution, climate-sensitive infectious diseases and data systems that protect people's lives and livelihoods in a changing climate…

Sabin Vaccine Institute [14 Nov 2026]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

UNAIDS [14 Nov 2026]
http://www.unaids.org/en
News, Stories, Updates
Press Statement
SADC health ministers warn disruptive UNAIDS reform could jeopardize 2030 AIDS goal
GENEVA/DURBAN, 13 November 2026

UNICEF [to 14 Nov 2026]
https://www.unicef.org/media/press-releases
Latest press releases, news notes and statements [Selected]
News note 13 November 2026
Fast facts: Ebola's toll on children six months into the outbreak and response – UNICEF
NEW YORK/DAKAR/KINSHASA, 12 November 2026, – Six months into the Ebola outbreak in eastern Democratic Republic of the Congo (DRC), significant progress has been made in expanding and strengthening the response. But with transmission continuing and the outbreak spreading to new areas, children continue to bear a he...

Press release 12 November 2026
Conflict and disease outbreaks deepen DR Congo's hunger crisis as record numbers are projected to face acute food insecurity
KINSHASA/ROME/NEW YORK/GENEVA, 13 November 2026 – , Severe hunger is expected to deepen in the Democratic Republic of the Congo (DRC), with a record 30.3 million people projected to face Crisis levels of acute food insecurity or worse (IPC Phase 3 or above) between January and June 2027, according to the latest I...

Press release 12 November 2026
UN launches Disaster Risk Financing Platform at COP31 to make humanitarian responses faster and more predictable
ANTALYA, Türkiye, 12 November 2026 –, The United Nations today launched a new initiative at the 31st United Nations Climate Change Conference (COP31) in Antalya, Türkiye, aiming to secure access to more than US$3 billion in risk financing to protect 75 million people and their livelihoods from potential climate sh...

Remarks 10 November 2026
UNICEF Executive Director Catherine Russell remarks at the Paris Peace Forum: Child Summit
NEW YORK, 10 November 2026 –, "President Macron, Excellencies, distinguished leaders, colleagues and many dear friends thank you for coming together around a very simple but urgent proposition: that this is a critical moment in history, and children must come first. "Across the globe, conflict, hunger, displacemen...

Remarks 10 November 2026
Drones and drought in Sudan: a combined assault on children like nothing seen before
GENEVA, 10 November 2026 -, "Drones and drought are closing in on Sudan's children from both sides. It is an assault unlike anything we have seen in Sudan's history. "In the last week of October, not a single day passed without an armed drone striking a power station in Sudan. Up to 15 were hit in the month. At th...

Press release 09 November 2026
Three children killed as heavy rains batter displaced families in Gaza – UNICEF
NEW YORK, 9 November 2026 –, Three children aged four, five and eight were killed along with their mother over the weekend when a sand dune collapsed onto their tent in Deir al-Balah, central Gaza, after heavy rainfall. The heavy rains directly affected more than 106,000 people, damaging or destroying shelters, ...

Unitaid [14 Nov 2026]
https://unitaid.org/

News releases
PAHO secures first-ever region-wide access agreements for HPV testing across Latin America and the Caribbean, with support from Unitaid
11 November 2026
… Under these first-ever regional access agreements, countries will be able to access high-quality molecular HPV tests through preferential pricing and a comprehensive support package, with participating countries expected to realize cost savings ranging from 30% to 70%. These technologies are now available through PAHO's Revolving Fund under harmonized regional conditions for all countries and territories in Latin America and the Caribbean…

News releases
Unitaid launches US$10.9 million initiative to protect essential health products from rising temperatures
09 November 2026
… The initiative, a consortium led by the United States Pharmacopeia (USP), will investigate which essential health products are vulnerable to heat and humidity today, which could become vulnerable as temperatures rise over the next 20–30 years, and what can be done to protect them.
The Safeguarding Heat Stability in Essential Life-Saving Drugs and Diagnostics project – known as SHIELD – will run from 2027 to 2030 and examine selected products relevant to HIV, tuberculosis, malaria, and maternal and child health…

Vaccine Equity Cooperative [nee Initiative] [14 Nov 2026]
https://vaccineequitycooperative.org/news/
News
No new digest content identified. [Last update Jun 30, 2023]

Vaccine Confidence Project [14 Nov 2026]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [14 Nov 2026]
http://www.chop.edu/centers-programs/vaccine-education-center
News
Vaccine Update Newsletter October 2026

Wellcome Trust [14 Nov 2026]
https://wellcome.org/
News. Opinion, Reports
No new digest announcements identified.

The Wistar Institute [to 14 Nov 2026]
https://www.wistar.org/news/press-releases
Press Releases
No new digest announcements identified.

World Bank [to 14 Nov 2026]
http://www.worldbank.org/en/news/all
News
No new digest content identified.

WFPHA: World Federation of Public Health Associations [14 Nov 2026]
https://www.wfpha.org/
Blog, Events
No new digest announcements identified.

World Medical Association [WMA] [to 06 Sep 025]
https://www.wma.net/news-press/press-releases/
Press Releases
WHPA urges COP31 to put health at the heart of climate action
09.11.28
Geneva, Switzerland: 9 November 2026 — As global leaders gather in Antalya, Türkiye, for the 31st United Nations Climate Change Conference (COP31), the World Health Professions Alliance (WHPA) is calling for health professionals and resilient health systems to be prioritised in global climate action.

World Organisation for Animal Health [WOAH/OIE] [14 Nov 2026]
https://www.oie.int/
Latest News
No new digest announcements identified.

::::::
::::::

ARM [Alliance for Regenerative Medicine] [14 Nov 2026]
https://alliancerm.org/press-releases/
Selected Press Releases
No new digest announcements identified.

BIO [14 Nov 2026]
https://www.bio.org/press-releases
Press Releases
BIO Unveils Seven-Point Plan to Secure America's Leadership in the Biotech Century
November 10, 2026
Action plan outlines the policies needed to ensure that the biotechnology sector remains a driving force for America's health, prosperity, national security, and geopolitical strength WASHINGTON (November 10, 2026) - The Biotechnology Innovation…

DCVMN – Developing Country Vaccine Manufacturers Network [14 Nov 2026]
http://www.dcvmn.org/
News, Events
No new digest announcements identified.

EFPIA – European Federation of Pharmaceutical Industries and Associations
https://www.efpia.eu/news-events/
News & Events
No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [14 Nov 2026]
https://internationalbiotech.org/
News
No new digest announcements identified.

IFPMA [14 Nov 2026]
https://ifpma.org/
News & Resources
Statement 12 Nov 2026
Innovative pharmaceutical industry welcomes B20 recognition of healthcare innovation as a driver of economic growth
12 November 2026, Geneva – The innovative pharmaceutical industry welcomes the Business20 (B20) Leaders' Statement and its recognition of long-term investment in research and development (R&D) and healthcare innovation as key priorities for continued economic growth and prosperity. The B20 USA Summit concluded in Washington with global business and policy leaders united around accelerating growth...

Position paper 9 Nov 2026
The use of artificial intelligence in regulatory activities – key areas and considerations
Scientific innovation is transforming the way medicines are discovered, developed, and evaluated, creating new opportunities to generate and analyze increasingly complex data and evidence. Regulatory science and regulatory systems need to evolve alongside these advances to ensure that scientific innovation can be effectively translated into innovative medicines for patients. Against this backdrop, artificial intelligence offers.

International Alliance of Patients' Organizations – IAPO [14 Nov 2026]
https://www.iapo.org.uk/news
Press and media [Selected]
No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest announcements identified.

PhRMA [14 Nov 2026]
http://www.phrma.org/
Press Releases
No new digest announcements identified.

::::::

::::::

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements
We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.
`

AstraZeneca
Press Releases - No new digest announcements identified.

Bavarian Nordic
Latest News
November 13, 2026
Henrik Juuel to Step Down as Chief Financial Officer of Bavarian Nordic in 2027

BioCubaFarma – Cuba
Últimas Noticias - Website not responding at inquiry.

Biological E
News - No new digest announcements identified.

BioNTech
Press Releases - No new digest announcements identified.

Boehringer
Press Releases
Sustained health equity progress lifts Boehringer to rank 6th in Access to Medicine Index
November 10, 2026

CanSinoBIO
News - Website not responding at inquiry.

CIGB
Latest News - No new digest announcements identified.

CinnaGen – Iran
CinnaGen News - No new digest announcements identified.

Clover Biopharmaceuticals – China
News - No new digest announcements identified.

CSL Sequirus
News Releases - No new digest announcements identified.

Curevac
News - Website now directs to BioNTech site

Dailchi Sankyo
Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik
Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]
https://sputnikvaccine.com/ - No new digest announcements identified [Last: 31 Aug 2022]

GSK
Press releases for media
13 November 2026
Bexsero (4CMenB) receives positive CHMP opinion for one-dose Meningitis B booster for 10+ year olds
Recommendation based on data showing immune memory established following vaccination in infancy can be boosted up to 19 years later

EuBiologics, S Korea
News - Website not responding at inquiry.

HIPRA
Press releases - No new digest announcements identified.

JNJ Innovative Medicine [Janssen]
Press Releases - No new digest announcements identified.

Merck
News releases
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
November 13, 2026
Some children up to 24 months of age remain vulnerable to severe RSV in their second RSV season – underscoring the importance of preventive options for this at-risk population
ENFLONSIA is Merck's FDA-approved extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants who are born during or entering their first RSV season.

Moderna
News and Blog Posts
November 12, 2026 7:00 AM
Moderna Outlines Next Phase of Growth at Analyst Day

November 11, 2026
Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
…commercial growth opportunities in 2027 and beyond include:
- Seasonal influenza: Following U.S. and Canadian approvals of mFLUSIVA® in 2026, Moderna is preparing for a broader commercial launch during the 2027-2028 respiratory season.
- European expansion: With four approved respiratory vaccines in the European Union, Moderna is positioned for additional growth as a competitor COVID-19 vaccine contract expires.
- Strategic partnerships: Long-term agreements in the United Kingdom, Canada and Australia provide recurring revenue and support domestic manufacturing. New agreements in Mexico and Taiwan expand opportunities in Latin America and Asia-Pacific.
- Expanded respiratory portfolio: The Canadian approval of mCOFLU®, Moderna's combination influenza and COVID-19 vaccine (known as mCOMBRIAX® in the European Union), and European approval of mNEXSPIKE® create additional commercial opportunities.
- Oncology: Positive Phase 3 results for intismeran in adjuvant melanoma support preparations for potential commercialization and continued investment in additional indications.

Nanogen
News - *No new digest announcements identified.*

Novartis
News
Novartis ranks first place in 2026 Access to Medicine Index
Nov 10, 2026
- Novartis retains first place ranking among 20 sector peers for efforts to improve access to medicines
- First company to achieve No. 1 rank across all Technical Areas since Index began in 2008, achieving R&D score almost twice the sector average
- Recognizes progress to expand care for cancer and heart disease, Coartem® Baby, and next-gen antimalarial KLU156 (ganaplacide/lumefantrine)

Novavax
Press Releases - *No new digest announcements identified.*

Pfizer
Recent Press Releases - *No new digest announcements identified.*

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Samsung Biologics
Latest News - *No new digest announcements identified*

Sanofi Pasteur
Press Releases - *No new digest announcements identified.*

Serum Institute
News & Announcements - *No new digest announcements identified.*

Sinopharm/WIBPBIBP
News - *No new digest announcements identified.*

Sinovac
Press Releases - *No new digest announcements identified.*

SK Biosciences
Press Releases - *No new digest announcements identified.*

Takeda
Newsroom - *No new digest announcements identified.*

Valneva
Press Releases
November 10, 2026
Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®

November 9, 2026
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

WestVac Biopharma
Media - *No new digest announcements identified.*

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
Website *[No News/Announcements page identified]*

::::::
::::::

Contents [click to move among sections]
:: *Milestones, Perspectives*
:: *WHO*
:: *Organization Announcements*
:: *Journal Watch*
:: *Pre-Print Servers*

::::::
::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 17 2026 Issue 3
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

American Journal of Human Genetics
Nov 05, 2026 Volume 113 Issue 11p2205-2376
https://www.cell.com/ajhg/current
Editors' Corner
This month in The Journal
Paul W. Hook, Alyson B. Barnes

Cross-phenotype associations can arise through pleiotropy, a process by which a single gene influences multiple traits. Vertical pleiotropy occurs when the genetic effect on one trait directly mediates the effect on another trait, whereas horizontal pleiotropy arises when the genetic effect indirectly mediates multiple traits through distinct biological mechanisms. Existing approaches for detecting both vertical and horizontal pleiotropy were largely developed for common variants and

cannot determine whether shared gene-level rare variant burden association arises from concordant allelic effects or from distinct variants acting through different mechanisms.

In this issue, Lu et al. introduce ALLSPICE, a tool to identify heterogeneous effects of rare coding variants within pleiotropic genes that enables the distinction between horizontal and vertical pleiotropy. Application of ALLSPICE to rare variant summary statistics of hundreds of traits in the UK Biobank revealed that rare coding variants within the same gene can influence phenotypes in heterogeneous ways. ALLSPICE is computationally efficient and immediately applicable to existing rare variant association datasets.

Perspective *Open access*

Genetic data sharing by clinical laboratories in Canada: A position statement by the Canadian College of Medical Geneticists

Jordan Lerner-Ellis, et al.

Article summary

Clinical genetic data are increasingly central to diagnosis and treatment, yet Canadian laboratories lack practical guidance for sharing them responsibly. This CCMG position statement translates ethical, legal, and clinical principles into actionable recommendations for Canadian laboratories to share genetic data responsibly while supporting patient trust and advancing genomic medicine.

American Journal of Infection Control

October 2026 Volume 54 Issue 10 p1045-1142

http://www.ajicjournal.org/current

[Reviewed earlier]

American Journal of Preventive Medicine

November 2026 Volume 71 Issue 5

https://www.ajpmonline.org/current

[Reviewed earlier]

American Journal of Public Health

October 2026 116(10)

http://ajph.aphapublications.org/toc/ajph/current

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 115 (2026): Issue 4 (Oct 2026)

https://www.ajtmh.org/view/journals/tpmd/115/4/tpmd.115.issue-4.xml

[Reviewed earlier]

Annals of Internal Medicine

October 2026 Volume 179, Issue 10

https://www.acpjournals.org/toc/aim/current

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 359 October 2026

https://www.sciencedirect.com/journal/artificial-intelligence/vol/359/suppl/C
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 14 Nov 2026)
[No new digest content identified]

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 14 Nov 2026]
[No new digest content identified]

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 14 Nov 2026)
[No new digest content identified]

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 14 Nov 2026)
[No new digest content identified]

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 14 Nov 2026)
[No new digest content identified]

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 14 Nov 2026)
[No new digest content identified]

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 14 Nov 2026)
Managing vaccination hesitancy under performance-based accountability: a qualitative study of primary care in Türkiye
Sibel Sakarya
Mutlu Alpay
Mehmet Akif Sezerol
Research Open access 11 November 2026

Parental vaccine hesitancy in primary care in Bilecik, Türkiye: associations with health beliefs and 5C psychological antecedents—a cross-sectional study

Sabahat Coşkun
Research Open access 10 November 2026

Factors associated with HPV vaccination among female college students in China: a cross-sectional study
Wenqian Yang
Hanting Zhang
Kun Tang
Research Open access 10 November 2026

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 14 Nov 2026)
[No new digest content identified]

BMJ Evidence-Based Medicine
October 2026 - Volume 31 - 5
https://ebm.bmj.com/content/31/5
[Reviewed earlier]

BMJ Global Health
October 2026 - Volume 11 - 10
https://gh.bmj.com/content/11/10
[Reviewed earlier]

Bulletin of the Atomic Scientists
DIGITAL MAGAZINE - July 2026
https://thebulletin.org/magazine/2026-05/
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 104, Number 10, October 2026, 657-716
https://www.who.int/publications/journals/bulletin
Articles
[Reviewed earlier]

Cell
Oct 15, 2026 Volume 189 Issue 21 p6561-6898
https://www.cell.com/cell/current
[Reviewed earlier]

Cell and Gene Therapy Insights
September 2026 Issue Volume 12 Issue 8
https://www.insights.bio/cell-and-gene-therapy-insights/journal/283/volume-12-issue-8
[Reviewed earlier]

Child Care, Health and Development
Volume 52, Issue 6 November 2026
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 120, Issue 4 Pages: 817-1148 October 2026
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]

Clinical Therapeutics
November 2026 Volume 48 Issue 11 p1051-1184
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

Clinical Trials
Volume 23 Issue 5, October 2026
https://journals.sagepub.com/toc/CTJ/current
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 14 Nov 2026]
[No new digest content identified]

Contemporary Clinical Trials
Volume 169 October 2026
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/169/suppl/C
Clinical Trial Management and Optimization
[Reviewed earlier]

The CRISPR Journal
Volume 9 Issue 5-6, October/December 2026
https://journals.sagepub.com/toc/tcja/9/5-6
[New issue; No digest content identified]

Current Genetic Medicine Reports
Volume 14, Issue 1 December 2026
https://link.springer.com/journal/40142/volumes-and-issues/13-1
[Reviewed earlier]

Current Medical Research and Opinion
Volume 42, Issue 6, 2026

https://www.tandfonline.com/toc/icmo20/current
[Reviewed earlier]

Current Opinion in Infectious Diseases
October 2026 - Volume 39 - Issue 5
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
https://currentprotocols.onlinelibrary.wiley.com/journal/19348258
[Accessed 14 Nov 2026]
[No new digest content identified]

Cytotherapy
December 2026 Volume 28 Issue 12
https://www.isct-cytotherapy.org/current
[Reviewed earlier]

Developing World Bioethics
Volume 26, Issue 3 Pages: 133-255 September 2026
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 36, 2026 Issue 4
https://www.tandfonline.com/toc/cdip20/36/4?nav=tocList
[Reviewed earlier]

Development Policy Review
Volume 44, Issue 6 November 2026
https://onlinelibrary.wiley.com/toc/14677679/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 20 - 2026
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 50, Issue 4 October 2026
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

eBioMedicine
Volume 132 October 2026
https://www.sciencedirect.com/journal/ebiomedicine/vol/132/suppl/C
[Reviewed earlier]

EMBO Reports
Volume 27, Issue 21 November 2026
https://link.springer.com/journal/44319/volumes-and-issues/27-21
[New issue; No digest content identified]

Emerging Infectious Diseases
Volume 32, Number 9—September 2026
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 56 September 2026
https://www.sciencedirect.com/journal/epidemics/vol/56/suppl/C
[Reviewed earlier]

Epidemiology and Infection
Volume 154 - 2026
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 48, Issue 5 Pages: 1-53 September–October 2026
https://onlinelibrary.wiley.com/toc/25782363/current
Research and pregnant women :: AI models and research ethics oversight
[Reviewed earlier]

Ethics & International Affairs
Volume 40 - Issue 1 - Spring 2026
https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 33 2025
https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/33/suppl/Cc
[Reviewed earlier]

The European Journal of Public Health
Volume 36, Issue 5, October 2026

https://academic.oup.com/eurpub/issue/36/5
[Reviewed earlier]

Expert Review of Vaccines
Volume 25, 2026 Issue 1
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
September/October 2026 Volume 105, Number 5
https://www.foreignaffairs.com/issues/2026/105/5
[Reviewed earlier]

Forum for Development Studies
Volume 53, 2026 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Frontiers in Genetics
https://www.frontiersin.org/journals/genetics
[Accessed 14 Nov 2026]
Review Published on 13 Nov 2026
Governing genomic AI in the era of agentic systems
Hui-Qi Qu,Hakon Hakonarson

Perspective Accepted on 10 Nov 2026
When Algorithms Choose the Future: Genetic Matchmaking, Digital Intimacy, and the Emerging Genomic Ethics Challenge for Somali Youth
Ayuub Axmed
Maryan Aadan
Ilyas Abdullah khalif

Original Research Accepted on 09 Nov 2026
Human rights and DNA analysis: Complications in the criminal justice process
Tersia Oosthuizen
Loene Monique Howes
Rob White

Frontiers in Genome Editing
https://www.frontiersin.org/journals/genome-editing
[Accessed 14 Nov 2026]
Editorial Accepted on 11 Nov 2026
Genome Editing in Plants: Novel Approaches and Emerging Challenges
Pawan Kumar Sharma
Jasmine M Shah

Editorial Accepted on 10 Nov 2026

Editorial: Recent Advances in Genome Editing Technology and Its Multifaceted Applications in Medicine, Agriculture, and Cosmetics

Edina Poletto
Siheng Tao
Lisong Ma
Kaihui Lu
Xinyu Ling

Frontiers in Medicine
https://www.frontiersin.org/journals/medicine/volumes?volume-id=1657
Accessed 14 Nov 2026]
[No new digest content identified]

Gene Therapy – Nature
Volume 33 Issue 5, September 2026
https://www.nature.com/gt/volumes/33/issues/5
[Reviewed earlier]

Genetics in Medicines
Volume 28, Issue 10 October 2026
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/28/issue/10
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 14 Nov 2026]
[No new digest content identified]

Global Health Action
Volume 19, Issue 1 (2026)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
https://pmc.ncbi.nlm.nih.gov/search/?term=%22Glob%20Health%20Sci%20Pract%22%5Bjournal%5D
[No new digest content identified]

Global Legal Monitor & Legal Reports – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc
[Accessed 14 Nov 2026]
[No new digest content identified]

Global Public Health
Volume 21, Issue 1 (2026)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 14 Nov 2026]
Global health diplomacy as a causal mechanism: a framework linking political determinants of health to population outcomes
Shawna Novak
Susana Orrego Villegas
Tim Patterson
Review Open access 13 November 2026

Health and Human Rights
Volume 28, Issue 2, June 2026
https://www.hhrjournal.org/volume-28-issue-1-june-2026/
Special Section: Children's Right to Health
[Reviewed earlier]

Health Economics, Policy and Law
Volume 21 - Issue 3 - July 2026
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 41, Issue 9, October 2026
https://academic.oup.com/heapol/issue/41/9
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 14 Nov 2026]
[No new digest content identified]

Human Gene Therapy
Volume 37 Issue 19-20, October 2026
https://journals.sagepub.com/toc/hgta/37/19-20
[Reviewed earlier]

Humanitarian Practice Network
https://odihpn.org/
[Accessed 14 Nov 2026]
[No new digest content identified]

Immunity
Nov 10, 2026 Volume 59 Issue 11 p2865-3130
https://www.cell.com/immunity/current
[New issue; No digest content identified]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 14 Nov 2026]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
Latest articles
Cost-effectiveness of respiratory syncytial virus vaccines in post-marketing settings: a systematic review and meta-analysis
Mengyao Mu
Yang Deng
Yi Zhao
Review Open access 14 November 2026 Article: 117

International Health
Volume 18, Issue 5, September 2026
https://academic.oup.com/inthealth/issue/18/5
[Reviewed earlier]

International Human Rights Law Review
Volume 15 (2026): Issue 1 (Jun 2026)
https://brill.com/view/journals/hrlr/hrlr-overview.xml
[Reviewed earlier]

The International Journal of Children's Rights
Volume 34 (2026): Issue 2 (Jun 2026)
https://brill.com/view/journals/chil/34/2/chil.34.issue-2.xml
Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol. 13 No. 10 (2026): October 2026
https://www.ijcmph.com/index.php/ijcmph/issue/view/141
Articles
[Reviewed earlier]

International Journal of Epidemiology

Volume 55, Issue 5, October 2026
https://academic.oup.com/ije/issue/55/5
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 19, Issue 2 22 April 2026
https://www.emerald.com/ijhrh/issue/19/2
[Reviewed earlier]

JAMA
November 10, 2026, Vol 336, No. 18, Pages 1585-1692
https://jamanetwork.com/journals/jama/currentissue
[New issue; No digest content identified]

JAMA Health Forum
October 2026, Vol 7, No. 10
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

JAMA Pediatrics
October 2026, Vol 180, No. 10, Pages 1055-1174
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
September 2026 - Volume 24 - Issue 9
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
October 2026 Volume 79 Issue 4 p451-602
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 85 (2026)
https://www.jair.org/index.php/jair
[Reviewed earlier]

Journal of Community Health
Volume 51, Issue 5 October 2026
https://link.springer.com/journal/10900/volumes-and-issues/51-5
[Reviewed earlier]

Journal of Development Economics
Volume 184 January 2027
https://www.sciencedirect.com/journal/journal-of-development-economics/vol/184/suppl/C
[New issue; No digest content identified]

Journal of Empirical Research on Human Research Ethics
Volume 21 Issue 4, October 2026
http://journals.sagepub.com/toc/jre/current
Empirical Studies of Stakeholder Perspectives on Selected Issues in Research Ethics
[Reviewed earlier]

Journal of Epidemiology & Community Health
September 2026 - Volume 80 - 9
https://jech.bmj.com/content/80/9
[Reviewed earlier]

Journal of Evidence-Based Medicine
September 2026 - Volume 80 - 9
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 22, Issue 1 (2026)
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 37, Number 4, November 2026
https://muse.jhu.edu/issue/57969
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 28, Issue 5 October 2026
https://link.springer.com/journal/10903/volumes-and-issues/28-5
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 24, Issue 3 (2026)
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of International Development

Volume 38, Issue 7 Pages: 1097-1289 October 2026
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

Journal of Law, Medicine & Ethics
Volume 54 - Issue 3 - Fall 2026
https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue
Supported Decision-Making in Clinical Research
[Reviewed earlier]

Journal of Medical Ethics
October 2026 - Volume 52 - 10
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 13, Issue 2 (2026)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

The Journal of Pediatrics
Volume 296 September 2026
https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/296/suppl/C
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
Volume 19, 2026 Issue 1
https://www.tandfonline.com/toc/jppp20/19/1?nav=tocList
[Reviewed earlier]

Journal of Public Health Management & Practice
September/October 2026 - Volume 32 - Issue 5
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 47, Issue 3 September 2026
https://link.springer.com/journal/41271/volumes-and-issues/47-3
[Reviewed earlier]

Journal of the Royal Society – Interface
Volume 23, Issue 243 1 October 2026
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 33, Issue 7, October 2026
https://academic.oup.com/jtm/issue
Perspectives
Strategic preparedness for the FIFA World Cup 2026 in response to the Bundibugyo Ebola outbreak in the Democratic Republic of Congo
Rigin Sebastian and others

Meningitis burden and vaccine impact in the WHO Western Pacific Region, 1990–2023
Seungjae Byun and others

The Lancet
Nov 14, 2026 Volume 408 Issue 10568 p2037-2172
https://www.thelancet.com/journals/lancet/issue/current
The Lancet Commissions
A Lancet Commission on the Health and Poverty Alleviation Initiative in China
Wannian Liang…Margaret Chan, et al.
p2125-2168
Poverty alleviation is a pressing global challenge that is intricately linked with health, as emphasised by the Sustainable Development Goals (SDGs). In 2019, out-of-pocket health expenditure—health-care costs paid directly by individuals or households rather than covered by insurance or other third-party payers—pushed an additional 344 million people into poverty globally. In 2020, 724 million people were living in extreme poverty, defined as living on less than US$2·15 per person per day at 2017 purchasing power parity, 90 million more than the pre-COVID-19 pandemic UN projection. When prioritising economic development and growth, governments often overlook the intrinsic link between ill health and poverty, an oversight that is reflected in the poor integration of health into poverty-reduction strategies of low-income and middle-income countries

The Lancet Child & Adolescent Health
Oct 2026 Volume 10 Number 10 p687-776, e30
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Sep 2026 Volume 8 Number 9
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
Nov 2026 Volume 14 Issue 11
https://www.thelancet.com/journals/langlo/issue/current
Editorial
Is global health dead?
The Lancet Global Health

Articles

HIV service delivery after the PEPFAR and USAID HIV funding withdrawal in Uganda and Zimbabwe: an interrupted time-series study

Henry Cust, Sungai T Chabata, on behalf of Partners in Uganda and Zimbabwe

Summary

Background

In January 2025, the US Government froze foreign aid and halted the President's Emergency Plan for AIDS Relief (PEPFAR), the largest external funder of HIV services globally. Early modelling studies and rapid assessments warned of major harm to millions, but robust quantitative evidence from those who relied most on the lost funding has been absent. We aimed to estimate the effect of the US funding withdrawal on HIV prevention, pre-exposure prophylaxis (PrEP), testing, and treatment services provided by non-governmental organisations (NGOs) serving primarily key populations in Uganda and Zimbabwe.

Methods

In this interrupted time-series study, we used monthly and quarterly service-delivery data from NGOs in Uganda and Zimbabwe from January 2023 up to March 2026. All received stop-work orders and subsequent funding cuts. Core service indicators across prevention, PrEP, treatment, and testing were normalised into domain indices, in which 100 represents their mean 2024 amount. The main outcome was the change in these service indicators because of funding cuts. Specifying February 2025 as the interruption point, we estimated effects with an unweighted panel interrupted time-series (the organisation level) and a client-weighted interrupted time-series (the key-population level) on these indices.

Findings

Eight organisations agreed to participate; four were subsequently excluded for reasons of data quality, lack of funding impact, and location, with four subsequently included in this study. All four service domains showed large, sustained declines. Across both the unweighted and weighted specifications, prevention fell by 36·8–62·7 index points, PrEP by 43·0–71·6, treatment by 22·0–31·5, and testing by 58·7–63·8 index points in February 2025 (index points are equivalent to percentage change from mean 2024 amounts). 95% CIs excluded zero for all estimates except PrEP in the unweighted panel. Services remained substantially below the 2024 amount up to March 2026. The antiretroviral therapy humanitarian waiver attenuated treatment effects but did not prevent substantial decline.

Interpretation

The sudden withdrawal of US funding was followed by severe, sustained disruptions to HIV service delivery in Uganda and Zimbabwe across all major domains, with the largest declines in prevention, PrEP, and testing services for key populations. These results are the first quantitative findings on service-volume changes in NGOs whose US funding was terminated or sharply cut and illustrate the effect on the NGO-led, key-population layer of HIV services in sub-Saharan Africa. These services are crucial to people living with HIV to remain healthy and have a good quality of life. Urgent investment in service-continuity protocols and domestic financing is needed to prevent a rebound in HIV incidence.

Funding

The Josiah Charles Trent Memorial Foundation Endowment Fund, the Sanford School of Public Policy, and Duke Global Publications Fund.

Health Policy

Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials

Morten Ruhwald, et al.

Summary

Tuberculosis vaccine prevention-of-disease efficacy trials traditionally rely on symptom-triggered case detection. This approach captures only a subset of bacteriologically confirmed disease and can miss cases that occur between scheduled trial visits or outside trial procedures, slowing endpoint accrual and complicating interpretation of results. At the same time, the diagnostic landscape for tuberculosis is changing rapidly. Advances, including near point-of-care (NPOC) molecular assays using sputum and non-sputum specimens, portable chest radiography with computer-aided detection, and digital tools for

decentralised monitoring, now make symptom-agnostic screening strategies increasingly feasible in large clinical trials. A 2026 WHO policy recommending the use of NPOC molecular diagnostics for tuberculosis further highlights the relevance of these approaches. In this Health Policy paper, we outlined a framework for integrating symptom-agnostic screening into tuberculosis vaccine efficacy trials and reviewed emerging diagnostic technologies that could enable this transition. Using parameters informed by the placebo arm of the M72/AS01$_E$ phase 2b trial, we present a worked example illustrating a possible effect on endpoint detection and case-verification burden. In this illustrative scenario, an NPOC-based symptom-agnostic screening strategy was estimated to increase detection of bacteriologically confirmed tuberculosis endpoints by approximately 1·4-fold, as compared with that by symptom-based screening alone, although this finding should not be interpreted as a direct estimate of overall trial efficiency. Realising these benefits will require analytical validation of diagnostic tools, clinical qualification for trial use, and early alignment with regulators and policy bodies. If evaluated through staged evidence generation and implemented with stringent confirmation algorithms, then symptom-agnostic screening could support more interpretable assessments of vaccine impact across the bacteriological spectrum of tuberculosis disease while preserving endpoint specificity.

Lancet Infectious Diseases
Sep 2026 Volume 26 Number 9 p871-974, e321-e385
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Nov 2026 Volume 11 Number 11 e836-e942
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Nov 2026 Volume 14 Number 11 p935-1036, e60-e67
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 30, Issue 9 September 2026
https://link.springer.com/journal/10995/volumes-and-issues/30-9
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 46 Issue 7, October 2026
https://journals.sagepub.com/toc/MDM/current
[Reviewed earlier]

Medical Law International
Volume 26 Issue 3, September 2026
https://journals.sagepub.com/toc/MLI/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 104, Issue 3 Pages: 581-938 September 2026
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

Molecular Therapy
Nov 04, 2026 Volume 34 Issue 11 p6167-6704
https://www.cell.com/molecular-therapy/current
Editorial
Breakthroughs in cell and gene therapy: Innovations in therapeutic modalities for the CNS, targeted delivery, translation, and CMC
Allison M. Bradbury

Nature
Volume 659 Issue 8140, 12 November 2026
https://www.nature.com/nature/volumes/657/issues/8140
Editorial 11 Nov 2026
Biotech innovations are an opportunity to limit climate change
Agricultural biotechnology once found itself in opposition to environmental science. Now it could reduce the impact of food systems on global warming and biodiversity loss.

Nature Biotechnology
Volume 44 Issue 10, October 2026
https://www.nature.com/nbt/volumes/44/issues/10
[Reviewed earlier]

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 14 Nov 2026)
[Reviewed earlier]

Nature Genetics
Volume 58 Issue 10, October 2026
https://www.nature.com/ng/volumes/58/issues/10
[Reviewed earlier]

Nature Human Behaviour
Volume 10 Issue 9, September 2026
https://www.nature.com/nathumbehav/volumes/10/issues/9
[Reviewed earlier]

Nature Medicine
Volume 32 Issue 10, October 2026

https://www.nature.com/nm/volumes/32/issues/10
Editorial 14 Oct 2026
Making AI work in healthcare
Drawing on experiences across diverse settings, this issue of *Nature Medicine* explores the challenges of and lessons learned from the deployment of artificial intelligence models into healthcare.

Review Article 29 Sept 2026
Reproducibility in biomedical research
Reproducibility is a foundational principle of trustworthy science, but reproducible research practices are not consistently implemented. This Review summarizes the current landscape including efforts to harmonize terminology and implementation, persistent barriers and ecosystem responses.
Judy Zhong
Debra D'Angelo
Rainu Kaushal

Article Open Access 10 Aug 2026
Emergence of a Bundibugyo virus variant in the 2026 outbreak in the Democratic Republic of the Congo and Uganda
A phylogenetic analysis of 22 genomes from the recent Bundibugyo virus outbreak in the Democratic Republic of the Congo and Uganda suggests the outbreak was caused by a new zoonotic spillover event.
Adrienne Amuri-Aziza
Gradi Luakanda-Ndelemo
Pardis Sabeti

Nature Reviews Drug Discovery
Volume 25 Issue 10, October 2026
https://www.nature.com/nrd/volumes/25/issues/10
[Reviewed earlier]

Nature Reviews Genetics
Volume 27 Issue 10, October 2026
https://www.nature.com/nrg/volumes/27/issues/10
[Reviewed earlier]

Nature Reviews Immunology
Volume 26 Issue 9, September 2026
https://www.nature.com/nri/volumes/26/issues/9
[Reviewed earlier]

New England Journal of Medicine
Volume 395 No. 19 November 12, 2026
https://www.nejm.org/toc/nejm/medical-journal
Perspective
Mass Surveillance with Artificial Intelligence — A New Determinant of Health?
N. Peoples, K. Hoops, and E.W. Fleegler
AI is changing the fundamental nature of surveillance in ways that strain existing privacy law and put public health at risk. Medicine has a responsibility to confront these developments.

Review Article
Preventing Malaria Infections and Moving toward Malaria Elimination
A.M. Tchouatieu, T.N.C. Wells, and J. Achan

NEJM Evidence
Volume 5 No. 9 September 2026
https://evidence.nejm.org/toc/evid/current
NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
[Reviewed earlier]

njp Vaccines
https://www.nature.com/npjvaccines/
[Accessed 14 Nov 2026]
[No new digest content identified]

Pediatrics
Volume 158, Issue 5 November 2026
https://publications.aap.org/pediatrics/issue/158/5
[Reviewed earlier]

PharmacoEconomics
Volume 44, Issue 11 November 2026
https://link.springer.com/journal/40273/volumes-and-issues/44-11
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 14 Nov 2026)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 14 Nov 2026)
[No new digest content identified]

PLoS Global Public Health
https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60
(Accessed 14 Nov 2026)
[No new digest content identified]

PLoS Medicine

https://journals.plos.org/plosmedicine/
(Accessed 14 Nov 2026)

Effectiveness of pneumococcal vaccination campaigns in humanitarian settings: A modelling study

Kevin van Zandvoort, Mohamed O. Bobe, Abdirahman I. Hassan, Rachael Cummings, Abdihamid Warsame, Casey L. Pell, Mohamed Ismail Abdi, Saed Ibrahim, Catherine R. McGowan, E. Kim Mulholland, Catherine Satzke, Rosalind M. Eggo, Mohamed Abdi Hergeye, Francesco Checchi, Stefan Flasche

Research Article | published 11 Nov 2026 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004768

PLoS Neglected Tropical Diseases

http://www.plosntds.org/
(Accessed 14 Nov 2026)
[No new digest content identified]

PLoS One

http://www.plosone.org/
[Accessed 14 Nov 2026]

Vaccination status and its association with complications among the patients admitted with measles in the dedicated measles hospitals, Dhaka, Bangladesh

Arpita Goutam, Anamul Hasan, Md Abdullah Saeed Khan, Mohammad Ali Hossain Mahid, Sumaya Binte Masud, Habiba Babul, Lamisa Rahman, Amina Siddiqui, Salma Tasnim Luthfa, Samiha Nahar Tuli, Indrani Paul, M. Rashidul Bari, Abu Sayeed Md Saleh, Mohammad Delwer Hossain Hawlader

Research Article | published 11 Nov 2026 PLOS ONE
https://doi.org/10.1371/journal.pone.0353336

PLoS Pathogens

http://journals.plos.org/plospathoge ns/
[Accessed 14 Nov 2026]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

November 10, 2026 vol. 123 no. 45
https://www.pnas.org/toc/pnas/123/45
Research Article November 5, 2026

Trust as a hidden driver of epidemic-relevant behavior: Institution- and behavior-specific associations across 20 national survey waves

Compartmental models of infectious disease transmission make assumptions about human behaviors. Specifically, they parameterize interactions across population groups, assumed to have distinct epidemiologically relevant behavioral patterns, primarily ...

Alexander J. Zapf, George Dewey,[...] Mauricio Santillana

PNAS Nexus

Volume 5, Issue 10, October 2026
https://academic.oup.com/pnasnexus/issue/5/10
Perspective

Discovery as public infrastructure: Renewing the social contract for science
Sergio Carbajo and others

Scientific capacity built over generations is being weakened by abrupt political disruption just as discovery is becoming faster, more convergent, globally networked, and more socially consequential. Restoring funding and protecting scientific institutions are urgent, but not sufficient: the postwar compact that sustained discovery before its uses were known must be renewed for 21st-century conditions and made resilient to arbitrary disruption. We propose the Discovery Compact, a renewed social contract among government, science, industry, and the public that treats discovery as shared public infrastructure—capacity a plural society builds, tends, and holds in common across generations. It is organized around five criteria: (i) sustaining discovery as national infrastructure; (ii) enabling institutions to move at speed without sacrificing rigor; (iii) building scientific capacity through people, openness, and mobility; (iv) translating discovery without depleting its source; and (v) securing democratic legitimacy and institutional resilience. Together, these criteria direct policy toward durable scientific capacity and insulate against indiscriminate deregulation, compulsory commercialization, arbitrary institutional disruption, and political control of scientific judgment. This Perspective is not a legislative template but an invitation to a national and international process of protecting and renewing the institutions and infrastructure through which societies discover, generate, protect, and prepare.

Prehospital & Disaster Medicine
Volume 41 - Issue 1 - 2026
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 210 September 2026
https://www.sciencedirect.com/journal/preventive-medicine/vol/210/suppl/C
[Reviewed earlier]

Proceedings of the Royal Society B
Volume 293, Issue 2082 November 2026
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Public Health
Volume 258 September 2026
https://www.sciencedirect.com/journal/public-health/vol/258/suppl/C
[Reviewed earlier]

Public Health Ethics
Volume 18, Issue 2, July 2025
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Genomics
2026, Vol. 29, No. 1
https://karger.com/phg/issue/29/1

[Reviewed earlier]

Public Health Reports
Volume 141 Issue 5, September/October 2026
https://journals.sagepub.com/toc/phrg/141/5
[Reviewed earlier]

Qualitative Health Research
Volume 36 Issue 12, October 2026
https://journals.sagepub.com/toc/QHR/current
[Reviewed earlier]

Research Ethics
Volume 22 Issue 4, October 2026
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 14 Nov 2026]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Latest Articles
[No new digest content identified]

Risk Analysis
Volume 46, Issue 9 September 2026
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]

Risk Management and Healthcare Policy
https://www.dovepress.com/risk-management-and-healthcare-policy-archive56
[Accessed 14 Nov 2026]
[No new digest content identified]

Royal Society Open Science
Volume 13, Issue 10 1 October 2026
https://royalsocietypublishing.org/toc/rsos/current
[Reviewed earlier]

Science
Volume 394| Issue 6825| 12 Nov 2026
https://www.science.org/toc/science/current
Expert Voices
Ebola vaccine lessons
BY Seth Berkley 12 Nov 2026

Science and Engineering Ethics
Volume 32, Issue 5 October 2026
https://link.springer.com/journal/11948/volumes-and-issues/32-5
[Reviewed earlier]

Science Translational Medicine
Volume 18| Issue 874| 4 Nov 2026
https://www.science.org/toc/stm/current
Research Resources
Frequency of pharmacogenomic variation and medication exposures among participants in the All of Us Research Program
BY Andrew Haddad, All of Us Research Program Investigators
11 Nov 2026
Pharmacogenomic variants and actionable results are common among participants in the All of Us Research Program.

Scientific Reports
https://www.nature.com/srep/articles?type=article
[Accessed 14 Nov 2026]
[No new digest content identified]

Social Science & Medicine
Volume 405 September 2026
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/405/suppl/C
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 14 Nov 2026]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 47, Issue 5 October 2026
https://link.springer.com/journal/11017/volumes-and-issues/47-5
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 73 September–October 2026

https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/73/suppl/C
[Reviewed earlier]

Tropical Medicine & International Health
Volume 31, Issue 11 Pages: 1509-1714 November 2026
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 95 5 January 2027
https://www.sciencedirect.com/journal/vaccine/vol/95/suppl/C
Review article Open access
Exposure to natural disasters and vaccination indicators: a systematic review and directions for future research
Brittany Shea, Jeffrey Shaman
Article 129277
Abstract
Global routine childhood immunization has stagnated for almost two decades, leaving children vulnerable to both immediate and long-term health risks from infectious diseases. Identifying and mitigating impediments to childhood vaccination, such as barriers resulting from exposure to natural disasters, is vital for maintaining population health. While there is general understanding that disasters have the potential to disrupt vaccination services, well designed studies on the degree to which exposure to natural disasters affects vaccination indicators are limited. Understanding the effects of natural disasters on vaccine preventable diseases is an important area for future research as some natural disasters are becoming more frequent and intense due to climate change. To understand the current state of research on exposure to natural disasters and vaccination indicators (i.e., vaccination metrics including administration, coverage, rates), we conducted a systematic literature review of all literature in Embase, Google Scholar, PubMed, and Web of Science up until September 11–12, 2025. We aimed to identify relevant peer reviewed literature focusing on natural disasters and immunization and to assess them for relevance and inclusion. Seventeen studies met the criteria for inclusion. These studies examined the

Research article Open access
Brazilian version of the Vaccine Trust Gauge for adolescents
Vanessa Mara da Silva, Liza Motta Lima, Matheus Correia da Silva, Jaqueline Costa Lima, ... Bruna Hinnah Borges Martins de Freitas
Article 129270

Research article Open access
Childhood vaccination timeliness, under-immunization-for-age and measles effective immunity in Peru: a province and birth-cohort analysis of national survey data, 2004–2025
Jesús D. Rojas, Carolina R. Huarachi-Napa, Stephanie Z. Salazar-Buitron, Angelo P. Quillo-Diaz, Roger I. Calderón
Article 129286

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 14 Nov 2026]
Review

HPV Prevalence, Genotype Distribution and Vaccine Awareness in the Western Region of Saudi Arabia: A Narrative Review
Arwa A. Faizo and Mai M. El-Daly
Vaccines 2026, 14(11), 980;https://doi.org/10.3390/vaccines14110980 (registering DOI)
14 November 2026
Human papillomavirus (HPV) causes nearly all cervical cancers. This narrative review summarizes evidence on HPV prevalence, genotype distribution and vaccine awareness among women in the Western region of Saudi Arabia and considers its implications f..

Opinion
A Clearer Strategy for Responding to the Ebola Bundibugyo Outbreak Is Needed
Pierre M'Pele and Antoine Flahault
9 November 2026
The ongoing Ebola virus disease outbreak caused by Orthoebolavirus bundibugyoense (BDBV) in the Democratic Republic of the Congo highlights persistent gaps in global outbreak preparedness. Despite decades of experience with Ebola, delayed detection,..

Value in Health
October 2026 Volume 29 Issue 10 p1749-1932
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

World Development
Volume 206 October 2026
https://www.sciencedirect.com/journal/world-development/vol/205/suppl/C
[Reviewed earlier]

::::::
::::::

Contents [click to move among sections]
:: *Milestones, Perspectives*
:: *WHO*
:: *Organization Announcements*
:: *Journal Watch*
:: *Pre-Print Servers*

::::::
::::::

Pre-Print Servers

arXiv
https://arxiv.org/
[Accessed 14 Nov 2026]
[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics] workaround options]
No new digest content identified.

bioRxiv
https://www.biorxiv.org/content/early/recent
[Accessed 14 Nov 2026]
[Filters: Bioengineering, Genetics, Genomics, Neuroscience, Synthetic Biology]
Website not fully responding at inquiry…timing out from sequential citation exploration…exploring workaround options]
Pangenome Discoveries from Clinical Long-Read Genomes in Underrepresented Populations with Neurodevelopmental Disorders
Mohammad Amiruddin Hashmi, Nasna Nassir, Bipin Balan, Shehzad Hanif, Bassam Jamalalail, Mariam Eldesouky, Richa Tambi, Shuhd BinEshaq, K Dasuki Hansana Perera, Hanan Elsokary, Suhana Shiyas, Binte Zehra, Dia Advani, Solima Sabeel, Omar Bashir, Ahmed Khalifa, Aysha Ibrahim, Maryam Al Obathani, Shaima Alsuwaidi, Mohammed Yousuff, Nesrin Mohamed, Alexander Giddey, Naser Alshamsi, Wen-Wei Liao, Prajna Hebbar, Peter A. Audano, Amirul Islam, Omer S AlKhnbashi, Hosneara Akter, Shaoli Sarker, Reem K. Jan, Munazza Murtaza, Bakhrom Berdiev, Nelson C. Soares, Babacar Cisse, Shola Faniran, Nidheesh Chencheri, Haitham Elbashir, Syed Ali Bokhari, Rasha Buhumaid, Hanan Alsuwaidi, Karen Miga, Erich Jarvis, Mohamed Almarri, Human Pangenome Reference Consortium (HPRC), Stephen W. Scherer, Ammar Albanna, Maahil Arshad, Brett Trost, Egor Dolzhenko, Stefan S Du Plessis, Benedict Paten, Alawi Alsheikh-Ali, Mohammed Uddin
bioRxiv 2026.11.07.765034; doi: https://doi.org/10.64898/2026.11.07.765034

medRxiv
https://www.medrxiv.org/content/early/recent
[Accessed 14 Nov 2026]
[Filters: Epidemiology, Genetic and Genomic Medicine, Infectious Diseases (except HIV/AIDS), Medical Ethics, Public and Global Health]
[Website not fully responding at inquiry…timing out from sequential citation exploration…exploring workaround options]
PNEUMOCOCCAL CONJUGATE VACCINE SCHEDULES SHAPE SEROTYPE-SPECIFIC MEMORY B-CELL RESPONSES
Hugh Elliott Brown, Thanh V Phan, Zheng Quan Toh, Beth Temple, Cattram Duong Nguyen, Kien Vientrung, Hoang Van Anh Nguyen, Nhung Vu Pham Hong, Vo Thi Trang Dai, Kathryn Bright, Hau Phuc Tran, Rachel Ann Higgins, Nadia Mazarakis, Skyy Luu, Leanne Quah, Daniel G Pellicci, Thuong Vu Nguyen, Jeremy Anderson, Kim Mulholland, Paul Vincent Licciardi
medRxiv 2026.11.09.26367657; doi: https://doi.org/10.64898/2026.11.09.26367657

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 14 Nov 2026]
[Filter: All articles]
No new digest content identified.

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
No new digest content identified.

Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles
[Accessed 14 Nov 2026]
No new digest content identified.

Zenodo
https://zenodo.org/
[Zenodo is hosted by CERN which has existed since 1954 and currently has an experimental programme defined for the next 20+ years. CERN is a memory institution for High Energy Physics and renowned for its pioneering work in Open Access. Organisationally Zenodo is embedded in the IT Department, Collaboration Devices and Applications Group, Digital Repositories Section (IT-CDA-DR). Zenodo is offered by CERN as part of its mission to make available the results of its work (CERN Convention, Article II, §1).]
No new digest content identified

* * * *

Think Tanks

Brookings [to 14 Nov 2026]
http://www.brookings.edu/
Research, Events
No new digest content identified.

Center for Global Development [14 Nov 2026]
https://www.cgd ev.org/
WORKING PAPER
Beyond the Trillions: Making Limited Development Finance Work for Climate and the SDGs
Benedict Clements et al.
November 12, 2026
Estimates of the finance needed to meet the Sustainable Development Goals and climate commitments imply that external official finance to developing countries would need to rise by about $500 billion a year. We ask what a transfer of this size would mean for recipient countries. Allocating the addit...

Chatham House [to 14 Nov 2026]
https://www.chathamhouse.org/
Selected Analysis, Comment, Events
No new digest content identified.

Council on Foreign Relations [14 Nov 2026]
https://www.cfr.org/media/news-releases
New Releases [Selected]
No new digest content identified.

CSIS [to 14 Nov 2026]
https://www.csis.org/

Reports [Selected]
No new digest content identified.

IS Global [to 14 Nov 2026]
https://www.isglobal.org/en/press
Press releases
Early-life environmental factors linked to health across childhood and adolescence
13.11.2026

Very Strong El Niño Episodes Are Associated With Over 100,000 Additional Heat-related Deaths Worldwide per Year
10.11.2026

McKinsey Global Institute [to 14 Nov 2026]
https://www.mckinsey.com/mgi/overview
Featured Research
Report
The Achilles' heel of global trade: Building resilience where it matters most
November 12, 2026 -
International trade has been resilient, but important vulnerabilities lurk beneath the surface. Identifying and managing these Achilles' heels could help unlock new markets, products, and economic growth.

ODI [Overseas Development Institute] [to 14 Nov 2026]
https://odi.org/en/publications/
Publications
No new digest content identified.

Pew Research Center [to 14 Nov 2026]
https://www.pewresearch.org/
Latest Publications
No new digest content identified.

Rand [to 14 Nov 2026]
https://www.rand.org/pubs.html
Published Research [Selected]
Research Nov 11, 2026
Trust Unpacked: A diagnostic assessment of institutional trust
Trust Unpacked presents a conceptual and methodological foundation for understanding and assessing institutional trustworthiness.

Urban Institute [to 14 Nov 2026]
https://www.urban.org/research
New Research Publications – Selected
Playbook
Responsible Agentic AI Playbook

A Practical Guide for Nonprofits and Government Agencies
November 11, 2026

World Economic Forum [to 14 Nov 2026]
https://agenda.weforum.org/press/
Media [Selected]
No new digest content identified.

::::::
::::::

Public Consultations/Calls for Inputs/Calls for Papers

WMA - Declaration of Taipei Revision Launched *[Ongoing]*

...The Declaration of Taipei tries to achieve a balance between the rights of individuals giving their tissue or data for research and other purposes based on confidentiality and privacy rules while at the same time recognising that health data has become a very powerful tool for increasing knowledge.

In analysing the scenarios that already exist for the use (and misuse) of health data and biobanks, we came to the conclusion that the major risk scenarios may not result from science, but from the commercial, administrative or political use of such data. Limiting our guidelines to research only would have left us blind to the imminent risk of abuse from outside the field of medicine: commercialization, cost-cutting and potential political abuse.

Therefore, in contrast to the Declaration of Helsinki, this policy aims to address any use of health databases and biobanks excluding individual treatment and is not restricted to research. As physicians are the primary custodians of confidential health information, they feel an obligation towards their patients and other persons who entrust them with their data and specimens...

In April 2025, the WMA appointed a workgroup to initiate the revision process of this document. To encourage as much global participation in the revision process as possible, the WMA is collaborating with its members to host a series of regional meetings...

* * * *

Contents [click to move among sections]

:: Milestones, Perspectives
:: WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2026. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *